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ABSTRACT OF DISSERTATION

MOLECULAR MECHANISMS THAT MEDIATE METASTASIS SUPPRESSOR
ACTIVITY OF NM23-H1
Metastasis is the spread of cancer cells from the primary tumor to distant sites. It
is the most dangerous attribute of cancer, and also the principle cause of cancerrelated morbidity and mortality. Metastasis suppressor genes are a group of genes
that suppress tumor metastasis without significant effect on tumorigenicity. NM23 was
the first identified metastasis suppressor gene, and loss of its expression is a frequent
hallmark of metastatic growth in multiple cancers (e.g. melanoma, carcinomas of
breast, stomach and liver). NM23-H1 possesses at least three enzymatic activities,
including nucleoside diphosphate kinase (NDPK), histidine kinase (hisK), and a more
recently described 3’-5’ exonuclease (EXO). While the hisK has been shown to be
linked to the suppression of cell motility, the NDPK has been reported to be unrelated
to the suppression of metastatic potential indirectly. Relevance of EXO has not been
addressed. Other known 3’-5’ exonuclease are closely associated with DNA repair
functions, suggesting NM23-H1 may suppress mutations required for metastasis.
As a transcription factor, NM23 has been shown to modestly downregulate the
transcription on PDGF-A chain, a growth factor oncogene, either alone or in
association with another transcriptional factor, Pur

. At the same time, identification

of NM23-H1 as a 3’-5’exonuclease suggests the role of NM23-H1 in DNA repair.

Etoposide and cisplatin elicited nuclear translocation of H1 within 4 h in HeLa and
HepG2 cells, seen as accumulation of H1 in small intranuclear foci, strongly
suggesting the DNA repair function of H1. To investigate the enzymatic function
contributing to metastasis suppressor activity of H1, complementation system was
used by transfecting NM23-H1 with individually disrupted enzymatic function into 2
melanoma cell lines, 1205LU and WM793. Overexpression of H1 in 1205LU
suppressed lung metastasis in vivo without effect on indices of transformation (e.g.
proliferation, soft agar colonization). EXO- deficient H1 and NDPK-deficient H1 lost
suppression of lung metastasis, while hisK-deficient H1 maintained suppressor
activity. Consistent with the results in 1205LU cells, EXO-deficient H1 and NDPKdeficient H1 lost suppression of the progression of WM793 cells in protein-free
medium, while WT and hisK-deficient H1 prevented the progression. Taken together,
these data suggest that the NDPK and/or 3’-5’EXO activity of H1 inhibits the
progression of premetastatic cells to the metastatic phenotype, possibly via a DNA
repair function or other structural transactions with DNA.
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CHAPTER ONE
INTRODUCTION

1.1. Metastasis and genomic instability
Metastasis is the spreading of tumor cells from their primary sites to distant
locations. It may occur via the blood, a lymphatics route, or through the body cavities.
Because of the limited treatment options for metastatic disease, metastasis is the
principle cause of morbidity and mortality of cancer patients (reviewed in Steeg, 2003).
Metastasis is the end-result of a complicated, multistage process. Each of these
sequential steps is rate-limiting (reviewed in Shevde and Welch, 2003; reviewed in
Fidler, 2003). First, tumor cells detach from the primary tumor, invade the host stroma
and penetrate blood vessels (Intravasation). Secondly, after tumor emboli enter the
circulation, cells must survive shear forces, immune surveillance, or maybe nitric oxide
produced by cytokine-activated endothelial cells (Dong et al, 1994). Finally, surviving
tumor cells penetrate blood vessels (Extravasation) and colonize in the secondary site.
Metastases form with proliferation of tumor cells and angiogenesis (Figure 1 from
Fidler, 2003).
The majority of data show that metastasis is a highly selective process (reviewed
in Talmadge and Fidler, 1982; Talmadge et al., 1982) and is quite inefficient (reviewed
in Weiss, 1990). Progressing from premetastatic to metastatic state, a tumor cell must
overcome a series of barrier to finish all steps of metastasis. During the process of
evolution, tumor cells may have undergone many coordinated changes and acquired
genetic variability to become more malignant. Nowell (reviewed in Nowell, 1976)
suggested that increasing genetic instability of the evolving cells and associated
selection process result in accelerating tumor progression toward malignancy. This
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hypothesis was tested by Fidler group, and they found that high metastatic clone of
fibrosarcoma cells were phenotypically less stable than low metastatic clone.
Furthermore, the spontaneous mutation rate of high metastatic cells were determined
to have 3- to 7- fold increase as compared to their low metastatic counterparts. These
data support the hypothesis that tumor evolution could be the consequence of
acquired genetic alterations (Cifone and Fidler, 1981).
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Figure 1. The steps of the process of metastasis
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1.2. Metastasis suppressor genes and NM23
By definition, metastasis suppressor genes suppress the ability of tumor cells to
metastasize, without affecting their primary tumor growth characteristics. These genes
are identified by their decreased expression in metastatic tumor cells, compared with
their expression in non-metastatic cells (reviewed in Steeg, 2003). Since the
identification of the first metastasis suppressor gene, nm23, in 1988 by P.S. Steeg,
more than a dozen of metastasis suppressor genes have been identified, and their
functional data have been completed or not characterized yet (reviewed in Shevde and
Welch, 2003). Many high-throughput techniques have been used during the discovery
of these genes, such as differential display, microarrays, and serial analysis of gene
expression (SAGE).

A very instrumental method employed in identifying several

metastasis suppressor genes (e.g., BRMS1, KISS-1, MKK4, and CD44-s) is microcellmediated chromosome transfer (MMCT), a method to identify a chromosomal region
that has metastasis suppression function in vivo. In the case of genetic loss, transfer of
a single human tagged chromosome into metastatic cells, would suppress metastasis.
Identified metastasis suppressor genes can be validated by re-expression in
metastatic cell lines. Its re-expression should significantly inhibit metastasis, but have
no effect on primary tumor growth. Even though the number of metastasis suppressor
genes is continuing to grow, the roles they play in predicting the prognosis of
metastatic diseases as well as therapeutic strategies is not yet known.
NM23 was the first identified metastasis suppressor gene by screening cDNA
libraries of matched metastatic/non-metastatic murine melanoma cell lines by
substraction cloning (Steeg et al., 1988). NM23 stands for ‘non-metastatic clone 23
gene’. Loss of NM23 expression is linked to metastasis in multiple cancers (e.g.
melanoma, breast cancer, and stomach and liver carcinomas). The human NM23
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protein has sequence homology over the entire translated region with developmentally
regulated protein in Drosophila, encoded by the abnormal wing discs (awd) gene.
Mutations in awd cause abnormal tissue morphology and necrosis and widespread
aberrant differentiation in Drosophila, analogous to changes in malignant progression
(Rosengard et al., 1989). To date, eight NM23 family members have been identified,
designated NM23-H1 through NM23-H8 (Lacombe et al., 2000). Of these, only H1 and
H2 have been reported metastasis suppressor activity (Shevde and Welch, 2003).
NM23-H1 and NM23-H2 are 88% identical in sequence and map 4 kb apart on
chromosome 17q21-22 near the BRCA1 locus (De la Rosa et al., 1995). High
resolution X-ray structures indicate that NM23-NDPK enzymes are hexameric
consisting of subunits of 152 amino acids. These amino acids fold into four-stranded
antiparallel β sheets and surrounding α helices (reviewed in Postel, 1998) (Figure 2).
The Killer of prune (K-pn) mutation is located in awd (Dearolf et al., 1988) and
substitutes a serine for a proline in Drosophila NDP kinase (A.Shearn, personal
communication; Lascu et al., 1992). K-pn is a dominant lethal mutation (Orevi and
Falk, 1975) in flies carrying the prune eye colour mutation, which suggests that the
product of awd interacts with that of prune.

5

Figure 2. The structure representations of NM23-H1 (A) Amino acid sequence and
secondary structure assignment of NM23-H1 (B) Ribbon diagram of the NDPK/NM23H1 monomer. Helices, b-sheets, and K-pn loop are all labeled as indicated (C) Space
filling representation of the hexamer of NM23-H1. The key residues studied in this
project are demonstrated in both monomer and hexamer stuctures.
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NM23-H1 possesses at least three enzymatic activities, including nucleoside
diphosphate kinase (NDPK), histidine kinase (hisK), and a 3’-5’ exonuclease (EXO)
more recently described by our lab (Ma et al., 2002, 2004). Mutations of P96 or S120
of H1 lacking motility suppressive capacity upon transfection are deficient in histidinedependent protein phosphotransferase pathways in vitro, suggesting the hisK is linked
to the suppression of metastasis (Freije et al., 1997). Some indirect evidence has
demonstrated that the NDPK appears to be unrelated to metastasis suppression
(MacDonald et al., 1993), but this has not been tested directly. Relevance of EXO has
not been addressed. Other known 3’-5’ exonucleases are closely associated with DNA
repair functions and the maintenance of genomic integrity, and their loss would be
expected to cause increased mutation rates, suggesting NM23-H1 may have the
potential to suppress mutations required for metastasis.

1.3. 3’-5’ exonucleases and DNA repair
DNA replication is a highly organized process. DNA polymerases play an
essential role to maintain the integrity of the genome during this whole process.
Besides their 5’-3’ DNA synthesis function, many DNA polymerases (e.g. pol γ, pol δ
and pol ε) contain intrinsic proofreading 3’-5’ exonuclease activity. The role of 3’-5’
exonuclease is to proofread for the polymerase. Thus, this enhances the accuracy of
DNA synthesis and ensures the high-fidelity of DNA replication.
However, some 3’-5’ exonucleases are not “polymerase-associated”, and are,
thus, termed “autonomous 3’-5’ exonucleases” (reviewed in Shevelev and Hübscher,
2002). At least eight human autonomous 3’-5’ exonucleases have been identified in
mammals, including the protein TREX1, TREX2, p53, MRE11, RAD1, RAD9, APE1
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and VDJP. These exonucleases are thought to maintain the accuracy of DNA
replication and improve the relatively inefficient proofreading of polymerase-associated
exonuclease (the error rate of DNA polymerases in DNA synthesis is 10-4-10-5). They
may also assist exo-deficient polymerases under different cases of genotoxic stress
(such as, imbalance of dNTPs, action of DNA-damaging agents). However, none of
these functions has been demonstrated to date.
The spontaneous mutation rate in eukaryotic cells is low (estimated 10

-10

-10-12

per cell division) because of the base pairing rules recognized by the 5'-3' catalytic
function as well as the 3'-5' exonuclease proofreading function. Inactivation of any of
the gene products responsible for mechanisms that limit errors following DNA
replication results in an increased spontaneous mutation rate, termed the "mutator"
phenotype. The E.coli chromosome is replicated by the pol III holoenzyme. The
catalytic core of the enzyme contains the α subunit (the polymerase), the ε subunit
(3’-5’ exonuclease, product of the dnaQ gene), and the θ subunit (exonuclease
stabilizer) (reviewed in Kelman and O’Donnell, 1995). The enhanced expression of
dnaQ in wild-type E.coli results in about 100-fold decrease in frequency of
spontaneous mutations and 10-fold the frequency of UV-induced mutations (Ciesla
et al., 1990). These results suggest that increasing the cellular level of an
autonomous 3’-5’ exonuclease has an antimutator effect. Furthermore, if dnaQ was
mutated and transferred to the chromosome, replacing the wild-type gene, the cells
became inviable (Fijalkowska and Schaaper, 1996). These results demonstrated that
loss of proofreading exonuclease activity in dnaQ is lethal due to excessive error
rates (error catastrophe). Error catastrophe can occur when mutations accumulate to
such an extent that the entire system breaks down, which leads to strong mutator
phenotypes, cancer susceptibility and progression, and even inviability.
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The 3’-5’ exonuclease activity of NM23-H1 is dependent upon the presence of
Mg2+, is most pronounced with single-stranded substrates or mismatched bases at
the 3' terminus of double-stranded substrates, and is inhibited by both ATP and the
incorporation of cordycepin, a 2'-deoxyadenosine analogue, into the 3'-terminal
position (Ma, et al., 2004). Each of these is a common feature of other 3’-5’ EXOs
described previously, suggesting the possibility of NM23-H1 functioning as an
autonomous EXO. NM23-H1 possesses a Yx1D motif in the primary sequence,
revealing a strong homology to the EXO III motif found in most 3’-5’ EXOs, which is
Yx3D. Interestingly, E.coli NDPK retains the conventional Yx3D form. However, the
purpose of EXO activity of NM23-H1 in the cell and antimutator function remain to be
established. If NM23 is identified as both a 3’-5’ exonuclease and suppressor of the
mutator phenotype, that may provide the strong evidence of anti-metastasis and antiprogression of NM23 by decreasing mutation rates and thus maintaining genomic
stability.

1.4. Nucleoside diphosphate kinase and histidine kinase
Until recently, nucleoside diphosphate kinase (NDPK) was the only known
activity of NM23. NDPKs are ubiquitous enzymes catalyzing the transfer of
phosphate groups from triphosphate to diphsophate nucleotides, thereby maintaining
an appropriate balance of cellular NTP and dNTP levels.
NDP + ATP <=> NTP + ADP;
dNDP + ATP <=> dNTP + ADP,
NDPK uses energy of ATP to make triphosphates of ribonucleoside diphosphates
and deoxyribonucleoside diphosphates in both de novo and salvage biosynthesis.
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Fidelity in DNA synthesis and repair is largely dependent on a balanced supply
of deoxynucleotide triphosphate (dNTP) pools. It is therefore not surprising that
(d)NTP/(d)NDP pool imbalances are associated with mis-incorporation of DNA
synthesis, impairment of DNA repair, and thus compromised genomic integrity and
malignant growth (Ji and Mathews, 1991). Evidence shows that the mutator
phenotype of ndk (the structural gene for NDP kinase in E.coli) mutant cells is a
result of the dNTP imbalance (Zhang et al., 1996).

Furthermore, ATP/ADP and

GTP/GDP distribution across the cytosol is important for the control of signaling
pathways and actin-based mechanistic events involved in (tumor) cell motility,
growth and invasion. The ability of NDPK to supply GTP implies a role in G-proteinmediated signaling. It was reported that NDPK could serve as a guanine nucleotide
exchange factor as well as a GTPase-activating protein (Zhu et al., 1999). Rad is the
prototypic member of a new class of Ras-related GTPases. Purification of the
GTPase-activating protein (GAP) for Rad revealed NM23. In the presence of ATP,
GDP-Rad was reconverted to GTP-Rad by the nucleoside diphosphate (NDP) kinase
activity of NM23. Simultaneously, Rad regulated NM23 by enhancing its NDP kinase
activity and decreasing its autophosphorylation. The interaction of NM23 and Rad
provides a potential novel mechanism for bidirectional, bimolecular regulation in
which NM23 stimulates both GTP hydrolysis and GTP loading of Rad whereas Rad
regulates activity of NM23.
Besides NDPK activity, histidine kinase activity is another enzymatic function of
NM23-H1. Histidine protein kinases are well described in prokaryotes and lower
eukaryotes, where they form the ‘two-component’ signal transduction system. The
two-component regulator system is comprised of two proteins, a histidine protein
kinase (sensor protein), which is usually cell membrane-bound, and a partner
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response regulator (effector protein), which is in the cytoplasm and associated with
an

internal

response.

autophosphorylates

a

The

sensor

histidine

kinase,

residue

when

using

ATP

activated
as

a

by

a

signal,

phosphodonor.

Subsequently, the phosphorylated sensor kinase serves as a phosphodonor to a
conserved aspartate residue in the response regulator. The response regulator
protein in turn transmits the signal to the target protein to elicit an adaptive response
to the stimulus (Calera et al., 1998). The signaling pathway also includes a
phosphatase that dephosphorylates the response regulator, returning it to the
nonstimulated state, where it once again can respond to the signal. The
phosphatase may be the histidine kinase itself, the response regulator, or a separate
protein.
NM23-H1 has been reported to exhibit a histidine protein kinase activity, and
this activity correlated with motility suppression (Salerno et al., 2003). P96S mutant
NM23-H1-transfected MDA-MB-435 human breast carcinoma lines exhibited motility
levels at or above the control transfectants, indicating that these mutations can
abrogate the motility-suppressive phenotype of NM23-H1 (MacDonald et al., 1996).
This mutation exhibited normal autophosphorylation and nucleoside-diphosphate
kinase (NDPK) characteristics but deficient histidine kinase activity, suggesting that
histidine-dependent protein phosphotransfer activity of NM23-H1 may be responsible
for metastasis suppression effects (Freije et al., 1997).
Even though NM23-H1 is “sticky” and has been shown to associate with
numerous proteins (Salerno et al., 2003), the physiological substrates of NM23 are
still unknown. Kinase suppressor of Ras (KSR) was shown to interact with NM23-H1
in a manner consistent with a “two-component” signal transduction system
(Hartsough et al., 2002). NM23-H1 co-immunoprecipitated with KSR from lysates of
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transiently transfected 293T cells and in MDA-MB-435 breast carcinoma cells.
Autophosphorylated recombinent NM23-H1 was also shown to phosphorylate KSR in
vitro, with phosphoamino acid analysis identified serine as the major target residue.
Phosphorylated MAPK but not total MAPK levels were reduced in an nm23-H1
transfectant of MDA-MB-435 cells. The P96S kinase-deficient NM23-H1 transfectant
exhibited relatively high levels of activated MAP kinase, suggesting that the histidine
protein kinase activity of NM23-H1 is needed for suppression of MAP kinase
activation. Taken together, one hypothesis proposes that NM23-H1 promotes a
histidine protein kinase signaling cascade, results in a novel pattern of KSR
phosphorylation and diminishes its ability to facilitate MAP kinase activation (Salerno
et al., 2003).

1.5. DNA binding and transcriptional regulation
By screening of a cervical carcinoma cell complementary DNA library with a
DNA fragment containing PuF binding sites, human c-myc transcription factor PuF
was identified as NM23-H2 nucleoside diphosphate kinase (Postel et al., 1993). The
link between NM23 and the c-myc oncogene suggests that the NM23 protein can
function in vitro in the transcriptional regulation of c-myc expression, their alteration
or removal from the promoter may be necessary for activation of the c-myc gene
(Postel, 1998). Unlike typical DNA binding proteins that are involved in transcriptional
regulation, NM23-H2 has shown a preference for single-stranded polypyrimidine-rich
sequences (Hilderbrandt et al., 1995). In vivo, NM23-H2 binds to and activates the
translocated c-myc allele in Burkitt's lymphoma cells (Ji et al., 1995).
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Our laboratory first demonstrated that NM23-H1 binds to a silencer element in
the platelet-derived growth factor (PDGF) A-chain promoter and downregulates the
transcription of the PDGF A-chain gene (Ma et al., 2002). As a growth factor, PDGF
has been implicated in many forms of human cancer (reviewed in Silver, 1992) and
may play an active role in the progression of some cancers to the metastatic
phenotype. For example, overexpression of PDGF B-chain confers a tumorigenic
and metastatic phenotype to human T98G glioblastoma cells (Potapova et al., 1996),
while elevated levels of PDGF A-chain are correlated with angiogenic and metastatic
potential in human breast cancer cells and human melanoma cell lines (Westermark
et al., 1986; Anan et al., 1996).
Our lab has demonstrated that the A-chain gene is under the strong repressive
influence of multiple silencer elements, located both in the 5’-flanking sequence and
in the first intron (Liu et al., 1996). Further study revealed that a significant
component of the silencer activity could be attributed to a 31bp sequence, termed
the 5’-S1 nuclease-hypersensitive, or 5’SHS element (-1418 to -1388), and another
silencer to a 24 bp sequence in the first intron, designated as the intSHS. Such
nuclease-sensitive structures appeared in the promoter regions of many eukaryotic
genes are often correlated with the induction of cell specific transcription. Many of
these nuclease-hypersensitive transcriptional elements are characterized by
homopurine/homopyrimidine tracts, and the overrepresentation of these motifs in
eukaryotic genomes further suggests global involvement in transcription. Screening
of a HeLa cDNA expression library with the C-rich strand of a PDGF-A silencer
sequence (5'SHS) yielded three cDNA clones encoding NM23-H1. Transient
transfection analyses in HepG2 cells revealed that both NM23-H1 and -H2 repressed
transcriptional activity driven by the PDGF-A basal promoter (-82 to +8), and another
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negative regulatory region (-1853 to -883), which contains the 5'-SHS (Ma et al.,
2002). These studies demonstrate for the first time that NM23-H1 interacts both
structurally and functionally with DNA. They also indicate a role for NM23 proteins in
repressing transcription of a growth factor oncogene, providing a possible molecular
mechanism to explain their metastasis-suppressing effects.
Recently, NM23/NDPK was shown to bind to p53, WT1, and ING1 genes,
suggesting that this protein may act as antimetastatic factor by favoring their
transcription. Also, it was demonstrated that NM23 binds to the promoter of NM23H1, suggesting the presence of a feedback regulation system for the protein level in
the cells (Cervoni et al., 2006). All these results suggest that NM23/NDPK DNA
binding may be involved in the transcription regulation of these genes.

1.6. Project objectives
Despite extensive study, the molecular mechanisms underlying the metastasis
suppressor activity of NM23 are still not clear. The overall goal of this project has
been to elucidate those mechanisms with a particular focus on its H1 isoform (NM23H1).
Our first working model proposed that NM23s facilitate assembly of functional
silencer complexes (FSCs) at the 5’SHS and related intSHS elements by binding to
poly-purine/poly-pyrimidine motifs within their non-B-form DNA structures, and
inducing silencer-competent DNA topology. Loss of NM23 proteins during tumor
progression results in derepression of PDGF A-chain gene transcription, increased
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A-chain expression, and ultimately, enhanced tumor growth and metastatic potential
in at least some cancers.
In order to test this hypothesis, two single-stranded DNA binding proteins, Purα
and YB-1, were purified and EMSA was performed to identify that whether they could
bind to 5’SHS silencer element and NHE (nuclease hypersensitive element) basal
promoter region of PDGF A-chain as elements of FSCs. Transient transfection was
conducted to demonstrate transcription regulation of each single protein and their
combinations with NM23. Finally, ethylation interference footprinting was employed
to localize the binding site of Purα on NHE element.
NM23 H1 was shown to possess a modest downregulation function on the
PDGF A-chain gene, either on itself or with other single-stranded DNA binding
proteins, suggesting this transcriptional inhibition of PDGF is very modest. At the
same time, NM23-H1 was identified as a 3’-5’ exonuclease (3’-5’ EXO) in our lab. 3’5’ EXOs are well-accepted to play an essential role in maintaining genome integrity,
with their loss resulting in an increased mutation rate. Accumulated genetic
alterations are known to underlie tumorigenesis and metastasis, suggesting the
novel hypothesis that the 3’-5’ EXO of NM23-H1 may have potentially important
implications for metastasis suppression as well. So, the alternative hypothesis is that
loss of the 3’-5’ EXO activity of NM23-H1 compromises genomic stability, which in
turn, facilitates progression of the primary tumor cell to a metastasis-competent state
and continuation of the metastatic phenotype.
To test the second hypothesis, a panel of melanoma cells was screened and a
premetastatic cell line WM793 and a metastatic cell line 1205LU were chosen due to
their low expression of NM23-H1 and –H2. Both cell lines were used for our
16

complementation system by stably transfecting wild type NM23-H1 and mutant
variants, with disrupted 3’-5’ EXO, NDPK, and HisK activities, back into cells
respectively. Then, their metastasis suppressor activities were compared using in
vitro models of motility and invasiveness, and in vivo models of metastasis, to
determine which enzymatic activity contributing to the function of metastasis
suppression (Figure 3). Besides, NM23 nuclear translocation and nuclear foci
formation in response to DNA damage were investigated in both HepG2 and HeLa
cells.
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Figure 3. Schematic illustration of experimental design. In this complementation
system, melanoma cell lines were stably transfected with wild type NM23-H1 and
mutant variants, with disrupted 3’-5’ EXO, NDPK, and HisK activities, respevtively.
Metastasis suppressor activities of different transfected cells were compared using in
vitro models of motility and invasiveness, and in vivo models of metastasis, to
determine which enzymatic activity contributing to the function of metastasis
suppression. Transformation phenotype of all the transfected cells has also been
tested.
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CHAPTER TWO
NM23-H1 HAS ONLY A MODEST EFFECT ON TRANSCRIPTIONAL ACTIVITY OF
THE PDGF-A PROMOTER: IDENTIFICATION OF PURα AS A
TRANSCRIPTIONAL ACTIVATOR VIA INTERACTION WITH SINGLE-STRANDED
MOTIFS
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2.1. Introduction
Platelet-derived growth factors (PDGFs) are a family of glycoprotein dimers
comprised of four constituent polypeptides, designated PDGF-A, PDGF-B, PDGF-C
and PDGF-D (reviewed in Pietras et al., 2003). PDGF-A and PDGF-B exhibit
considerable amino acid sequence homology and are encoded by distinct genes
found on separate chromosomes (Bartram et al., 1984; Bonthron et al., 1988). The
PDGFs possess potent mitogenic, chemotactic and angiogenic properties that
contribute to normal embryonic development, cellular differentiation and wound
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healing. PDGF expression is usually under tight repressive control but is induced by
various forms of stress, such as tissue injury, inflammation, and acute exposure to
mitogens (including PDGF itself). Inappropriate PDGF expression is linked to a
variety of fibroproliferative disorders, with unregulated PDGF signaling representing
an oncogenic stimulus in many cancers (Schilling et al., 1998; Shamah et al., 1993).
PDGF-A expression is controlled to a significant degree via regulation of its
transcription rate (reviewed in Kaetzel, 2003). The PDGF-A promoter is highly GCrich and its activity is regulated via the binding of such transcriptional regulators as
the Sp/Kruppel-like factors (KLFs), early growth response gene (egr-1), Wilms tumor
protein 1 (WT1), GC factor 2, and nuclear factor I-X (NFI-X) to their respective
cognate response elements. The PDGF-A promoter also assumes unusual singlestranded conformations, especially in a region which has been termed the nucleasehypersensitive element (NHE; Ma et al., 2002) by virtue of its hypersensitivity to
single-strand-specific endonucleases (Wang et al., 1992). Nuclease-hypersensitive
elements have also been identified in other regions of the PDGF-A gene, including
two structurally similar silencer elements located upstream of the promoter (Liu et al.,
1996) and within the first intron (Wang et al., 1994); these have been designated the
5′-S1-hypersensitive (5′SHS) and intSHS sequences, respectively (Figure 4). DNA
binding proteins with specificity for single-stranded motifs in these promoter and
silencer elements have yet to be identified.
Our previous data indicated that H1 can bind to DNA, recognizing both the
5’SHS silencer and the NHE of the c-myc promoter, with a high affinity for single
stranded forms of elements. Thus, binding of H1 and H2 to DNA elements that
mediate either enhancement or repression appears to indicate that their function is
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related to the specific DNA sequence recognized. Both H1 and H2 have been shown
to bind members of the ROR/RZR family of nuclear orphan receptors, suggesting a
role in facilitating the docking of other transcription factors. A prominent example of
other transcription factor is the PUR family (α and β) of proteins that bind singlestranded G-rich motifs. Purα was recognized as a transcription activator for several
promoters, including human neurotropic JC virus (Chen et al., 1995), myelin basic
protein, FE65, and neuronal acetylcholine receptor genes (reviewed in Gallia et al.,
2000). Purα can function either as a repressor or activator depending on promoter
and cellular context, and has also been shown to interact with RNA (Gallia et al.,
2000). We proposed a model in which 5’SHS silencer activity and the promoter is
mediated by the binding of single-strand specific proteins (both G-rich and C-rich
strand binding proteins), which may serve to stabilize a DNA conformation required
for repressive interactions of the silencer with other factors that interact with the
5’SHS silencer and the promoter of the A-chain gene.
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Figure 4. Prominent nuclease-hypersensitive elements in the PDGF-A promoter
and proximal flanking regions. At the top of the figure, the four nucleasehypersensitive elements portrayed as unpaired loops are: the 5′SHS silencer (−1438
to −1388), a serum response element (SRE; −477 to −468), the nucleasehypersensitive promoter element (NHE; −100 to −40), and the intron SHS silencer
(intSHS; +1605 to +1630). Expanded below the promoter region is the nucleotide
sequence of the NHE, within which the boundaries of 12 consensus Purα binding
sites (GGN, where N is not a G) are identified with black lines above the sequence.
The four consensus Sp1 binding sites (Sp-A through Sp-D) are identified with black
boxes. The TATA box is shown in bold upper case letters.
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2.2. Materials and methods
2.2.1. Cell culture and transient transfection assays
Plasmids pAC261 and pACF11 have been described (Kaetzel et al., 1994).
Transient transfections in HepG2 cells were conducted with 5×105 per 60 mm dish
using Lipofectamine (Invitrogen). Transfection efficiency was normalized by
cotransfection with RSV β-gal (1 μg), a plasmid expressing β-galactosidase (β-gal).
Cells were harvested 48 h after transfection, with determination of chloramphenicol
acetyltransferase (CAT) and β-gal activities conducted as described (Kaetzel et al.,
1994). Mouse embryo fibroblast cell lines (MEFs) were derived from wild-type mice
(Purα +/+) and a line harboring targeted ablation of both (Purα −/−) Purα gene copies
(Khalili et al., 2003). Cells were transfected with pAC261-luciferase and the Renilla
luciferase plasmid, phRL-SV40, using the liposomal reagent, Tfx-10 (Promega). After
48 h, activities of firefly and Renilla luciferase were assayed using the dual luciferase
system as described by the manufacturer (Promega). Transfections were conducted
in duplicate with three or more replicate experiments.

2.2.2. Electrophoretic mobility shift assay (EMSA)
Expression of GST-Purα in Escherichia coli and its purification have been
described previously (Gallia et al., 1998). Binding reactions for EMSAs were
conducted in a 20 μl volume at room temperature for 30 min. Reactions contained
20,000 cpm (20–40 fmol) of oligodeoxyribonucleotides, 100 ng of purified GST-Purα,
and 1 μg of poly(dI–dC) as nonspecific competitor. Protein–DNA complexes and
radiolabeled probes were resolved by electrophoresis through 6% polyacrylamide
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gels in 0.5X TBE buffer (45 mM Tris borate, 1 mM EDTA, pH 8.3), with radiolabeled
bands

visualized

by

phosphorimaging

(Molecular

Dynamics).

Oligodeoxyribonucleotide sequences employed were: 5′SHS, 5′-CTA GAG ACG
TGG GGA GGG GGC CTG CAG GTG TGT-3′; PDGF-A NHE, 5′-CTA GAG GGG
GCG GGG GCG GGG GCG GGG GAG GGG-3′; non-specific competitor R1, 5′-GTA
CGT ACG TAC GTA CGT ACG TAC GTA CGT ACG T-3′.

2.2.3. Ethylation interference footprinting
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P-endlabeled NHE (G-rich sense strand, −104 to +6) was modified with N-

ethyl-N-nitrosourea as described previously (Maul et al., 1998). Binding reactions
were scaled up from EMSA conditions by approximately 10-fold (200 ng of GSTPurα, 10 μg of poly (dI–dC), 0.4 pmol of probe). Protein-bound and free DNA were
separated by nondenaturing electrophoresis, followed by autoradiography and
electroelution of bands. Piperidine cleavage products were dried under speed
vacuum and subjected to three cycles of resuspension in H2O and drying. DNA
fragments were suspended in formamide loading buffer, resolved by electrophoresis
through 8% polyacrylamide sequencing gels, and visualized by phosphorimaging.

2.2.4. RNA isolation and real time PCR
Purα +/+ and Purα −/− MEFs were incubated in the presence or absence of
10% fetal bovine serum (FBS) for the times indicated in the text. One μg of total RNA
was reverse transcribed using a SuperScript First strand synthesis kit for RT-PCR
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(Invitrogen). DNA products from reverse transcription reactions were diluted with
H2O for measurement of PDGF-A (1:10) or 18S (1:1000) mRNAs by real-time PCR.
A relative standard curve was made by diluting the cDNA product from a single
sample from 1 pg to 100 ng. Analysis was conducted with the ABI Prism Sequence
Detection System 7700 analyzer, with relative initial RNA concentrations determined
from Ct values based on the standard curve.

2.3. Results
2.3.1. Purα binds to G-rich strands of the 5′SHS silencer and NHE of the PDGF-A
gene
The human PDGF-A gene contains at least four paranemic elements that are
highly GC-rich and contain multiple GGN repeat sequences (Figure 4), consensus
binding sites for Purα (Gallia et al., 2000). To assess binding of Purα to G-rich
strands of the 5′SHS silencer (Liu et al., 1996) and nuclease-hypersensitive promoter
element NHE (Ma et al., 2004), EMSAs were conducted with GST-tagged human
Purα (GST-Purα). IPTG treatment resulted in strong induction of a 66 kDa band
corresponding to GST-Purα (Figure 5A), which was purified using GSH-Sepharose
chromatography and its identity confirmed by immunoblot analysis with anti-GST
antibody (Figure 5B). Incubation of GST-Purα (100 ng) with the single-stranded, Grich strand of the PDGF-A NHE sequence resulted in the formation of a complex
(Figure 5B, lane 2) not obtained with GST polypeptide alone (Figure 5B, compare
lanes 7 and 8). Unlabeled NHE efficiently displaced labeled NHE from the

25

complexes (IC50<1 nM; Fig. 5B, lanes 3–5), indicating high affinity binding of GSTPurα to the NHE sequence. Displacement of radiolabeled 5′SHS with unlabeled
homologous competitor was also efficient (lanes 11–13). Specificity of binding
between GST-Purα and the NHE and 5′SHS motifs was indicated by the lack of
displacement with an irrelevant DNA sequence (lanes 6 and 14).
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Figure 5. Purα binds to G-rich strands of the 5′ SHS silencer and NHE with high
affinity and nucleotide sequence-selectivity. (A) Expression and purification of
GST-Purα. SDS-PAGE analysis of protein lysates from E. coli expressing
recombinant GST-Purα (left), obtained before (pre-ind.) and after (post-ind.) IPTG
induction. At right is the analysis of GST-Purα protein obtained by GSH-sepharose
affinity purification. Purified GST-Purα was subjected to SDS-PAGE and either
stained with Coomassie blue (1 μg GST-Purα, Coom.) or analyzed by Western blot
(100 ng GST-Purα, WB) with anti-GST antibody. (B) EMSA of GST-Purα binding with
the NHE promoter (top) and 5′SHS silencer (bottom) elements. GST-Purα (100 ng)
was incubated with a
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P-endlabeled oligodeoxyribonucleotide corresponding to the

G-rich sense strand of the NHE element (32P-NHEs), either in the absence (lane 2)
or presence of 50- (lane 3) or 100-fold (lane 4) molar excess of unlabeled
homologous competitor DNA. An irrelevant 33 nt oligodeoxyribonucleotide (NS, lane
5) was employed as a negative control. The same experimental paradigm was
employed in the analysis of GST-Purα binding to the G-rich strand of the 5′SHS
(5′SHSs; lanes 6–10). (C) Ethylation interference footprinting (EIF) analysis of
binding between GST-Purα and the NHE. Ethylated,
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P-endlabeled NHEs probe

was incubated with affinity purified GST-Purα and subjected to nondenaturing
electrophoresis to separate bound and free DNA. Shown are products obtained
following piperidine cleavage at guanine residues of free and bound probes, and
ethylated probe alone. At left are the footprint dimensions (FP) obtained, with the
location of Sp1 site A identified at right.
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2.3.2. Localization of Purα binding to the PDGF-A NHE sequence by ethylation
interference footprinting analysis
To localize nucleotide residues essential for binding of Purα to the NHE
sequence, ethylation interference footprinting (EIF) was conducted. EIF permits
single nucleotide resolution mapping of protein contacts with DNA, primarily at
guanine residues (Büning et al., 1995 and Maul et al., 1998). A single-stranded DNA
corresponding to nucleotides −104 to −6 was radiolabeled, ethylated, and incubated
with purified GST-Purα. Interference with Purα-NHE complex formation was evident
when residues located between −91 and −77 were ethylated, seen as a decrease in
intensity of bands in the bound relative to the free lane (Figure 5C). The footprinted
region contains a multitude of the GGN motifs characteristic of Purα binding sites
(see Figure 4). Footprinting was most pronounced at residues −89 through −82,
coinciding with two GGN repeats (GGA GGC) and one of the four consensus Sp1
sites (Sp-A) of the NHE.

2.3.3. Forced expression of Purα upregulates transcriptional activity of the NHE
Having shown Purα binds in vitro with high affinity and DNA sequenceselectivity to the G-rich strands of the NHE and 5′SHS elements of the PDGF-A
gene, we sought to determine whether the protein could regulate the respective
transcriptional activities associated with these elements. To this end, the effects of
forced Purα expression on reporter constructs containing these elements were
assessed by transient transfection analysis in HepG2 (human hepatoma) cells.
HepG2 cells were employed as they exhibit a significant PDGF-A promoter activity
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upon which either enhancement or repression could be observed (Maul et al., 1998).
Purα expression resulted in a nearly 3-fold induction in transcription mediated by a
−261 to +8 fragment of the PDGF-A promoter region, which contains the NHE
(Figure 6A). A similar effect (2.5-fold) was also seen with a shorter PDGF-A
promoter fragment (−84 to +8; Figure 6B) containing only the NHE and TATA motifs,
localizing the region necessary for Purα induction to the NHE. Purα expression
resulted in a much smaller, albeit statistically significant (1.3-fold) induction in Rous
sarcoma virus promoter activity (Figure 6C), indicating the specificity of Purαmediated induction of NHE activity. Constructs in which the 5′SHS was either
relocated adjacent to the −261 promoter fragment, or studied in the context of a 1.8
kb promoter fragment, exhibited the same 2.5–3-fold enhancement to forced Purα
expression (data not shown). Thus, Purα does not appear to interact functionally with
the 5′SHS silencer, despite its affinity for the element in vitro. Induction of NHE
activity by Purα dominated over the modest repressive activity of NM23-H1 (Figure
6A), an inhibitor of NHE activity in HepG2 cells (Ma et al., 2002). Expression of YB-1,
which cooperates with Purα to activate the viral lytic control element of the human JC
polyomavirus (JCV; Chen et al., 1995) and which binds with high affinity to the C-rich
strand of the NHE in vitro (data not shown), had no effect on NHE activity alone or in
combination with Purα. The ability of YB-1 to bind the NHE sequence suggests that it
may be relevant in some physiological contexts, such as endothelial cells, in which
the YB-1 family member DNA binding protein B (dbpB) has been shown to activate
the PDGF-B promoter (Stenina et al., 2000).
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Figure 6. Forced expression of Purα upregulates PDGF-A promoter activity. (A)
HepG2 cells were transfected with the PDGF-A chain promoter-CAT reporter
construct (pAC261cat) shown above the panel. Values (relative CAT activity)
represent the ratio of CAT activity divided by β-galactosidase (β-gal) activity obtained
by cotransfection with the control plasmid, pRSV-βgal. Cells were transfected with
the various combinations of vectors driving expression of Purα, NM23-H1 and YB-1,
as indicated. (B) Effects of Purα expression on activity of the −82 to +8 PDGF-A
promoter subfragment. (C) Effects of Purα expression on activity of the Rous
sarcoma virus enhancer-promoter. Asterisks denote means that are significantly
different (p≤0.05) from that obtained with pAC261cat (panels A and B) or pRSV-βgal
(panel C) alone.
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2.3.4. Purα expression is required for optimal expression of PDGF-A gene: studies in
MEFs derived from Purα knockout mice
To further establish the relevance of Purα to regulation of PDGF-A gene
transcription, NHE activity and PDGF-A mRNA levels were compared in embryo
fibroblasts (MEFs) derived from wild-type and Purα knockout mice (Khalili et al.,
2003). The mouse and human PDGF-A promoters are very similar in nucleotide
sequence, with the mouse version also highly GC-rich and harboring at least two of
the four Sp1 motifs found in the human gene (Figure 7A). Of note is the conservation
of sequence in the mouse gene corresponding to −86 to −81 of the human gene, the
area of strongest Purα binding identified by EIF analysis. Transcriptional activity of
the −261 to +8 fragment of the human PDGF-A gene, which contains the NHE, was
reduced by ~30% in MEFs derived from mice homozygous (−/−) for the Purα
knockout mutation relative to the wild-type (+/+). This indicates a role for Purα in
maintaining transcriptional tone of the PDGF-A promoter in fibroblasts and thus, by
inference, possibly other cell types.
To confirm whether the effects of Purα expression on PDGF-A promoter activity
are manifested in expression of the endogenous PDGF-A gene, steady-state
concentrations of PDGF-A mRNA were measured in MEFs derived from wild-type
and Purα −/− mice using real-time polymerase chain reaction (RT-PCR) analysis
(Figure 7B). Following 24 h of serum-deprivation, −/− MEFs exhibited a 35% lower
level of PDGF-A mRNA than wild-type MEFs. To examine whether Purα might
participate in the well-documented induction of PDGF-A expression and proximal
promoter activity in response to mitogen stimulation (reviewed in Kaetzel, 2003),
mRNA concentrations were also measured following administration of fetal bovine
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serum (FBS), a potent inducer of PDGF-A expression. In wild-type MEFs, PDGF-A
mRNA levels were induced significantly by FBS within 2 h and peaked within 4 h,
falling back to near baseline levels by 24 h. FBS induced mRNA concentrations in
−/− MEFs to levels comparable to those seen in wild-type MEFs at 2, 4 and 8 h posttreatment. At 24 h, however, mRNA levels in the −/− MEFs fell to concentrations
significantly below that of the corresponding treatment time in wild-type MEFs,
consistent with their relative difference prior to FBS treatment (panel C). Thus, Purα
is necessary for optimal PDGF-A expression under basal conditions, but is not
required for optimal induction of the gene in response to exposure to FBS.
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Figure 7. Purα is required for optimal NHE activity and expression of PDGF-A
mRNA. (A) Nucleotide sequence alignment of the mouse and human PDGF-A
promoters. The sequences were obtained from the human (gi 37538282_c900071530) and mouse (gi38081379_c148280-127560) genome databases; both were
previously derived (Bonthron et al., 1988 and Rorsman and Betsholtz, 1992). Sp1
motifs are identified by shading and brackets. (B) Transient transfection analysis of
NHE activity in MEFs derived from wild-type (Purα +/+) and Purα knockout
(Purα −/−) mice. Values represent relative luciferase activities obtained with
pAC261luc, corrected for differences in transfection efficiency with the Renilla
luciferase reporter construct phRL-SV40. (C) Steady-state concentrations of PDGFA mRNA in MEFs from Purα +/+ and Purα −/− mice as determined by real-time
polymerase chain reaction analysis. (D) Inactivation of the Purα gene does not
influence induction of the murine PDGF-A gene by fetal bovine serum. Values in
panels C and D are expressed relative to those obtained in untreated Purα +/+ MEFs
(fold-change). Bars represent means±S.E.M. (n=5), with asterisks denoting
significant differences (p<0.05).
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2.4. Discussion
To date, the only transcription factors shown to interact with the PDGF-A
promoter, such as the positively acting Sp/Krüppel proteins and the repressive
factors WT1, GCF2 and NFI-X, bind to DNA in double-stranded form (reviewed in
Kaetzel, 2003). The considerable single-stranded (paranemic) character of the
PDGF-A promoter, however, suggested that single-stranded DNA binding proteins
might also play important roles in regulation of promoter activity. The current study
has provided the novel observation that Purα, a transcription factor with an affinity for
single-stranded GGN motifs, activates transcription of the PDGF-A gene via binding
interactions with the G-rich strand of the promoter. The NHE region of the PDGF-A
promoter contains at least 12 such GGN motifs (Figure 4), consistent with multiple
potential targets for Purα interaction. A subfragment of the PDGF-A promoter (−84 to
+8) containing eight of these motifs exhibits full transcriptional inducibility upon
forced expression of Purα, indicating this region represents a minimal Purα response
element. However, ethylation interference footprinting indicated that Purα also binds
with high affinity to a region found further upstream (−91 to −77) which contains a
single GGN motif, strongly suggesting these upstream sites may also be competent
for Purα responsiveness. Accordingly, a comprehensive mutagenic analysis of Purα
binding and transcriptional responsiveness of all 12 GGN motifs, singly and in
combination, might be informative in elucidating this complex molecular interaction.
Purα mRNA is expressed in all metazoan tissues examined to date (Johnson,
2003), suggesting potential for wide-ranging roles in the regulation of PDGF-A gene
transcription. The similarly ubiquitous patterns of expression for Sp1 and other
Sp/Krüppel proteins suggests the PDGF-A promoter may exist in an equilibrium
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between double-stranded (Sp-bound; moderate transcription) and single-stranded
(Purα-bound, higher transcription) states, as shown in the model of Figure 8. This
model is similar to that proposed for the myelin basic promoter (MBP) gene, where a
transcriptional repressor, MyEF-2, is displaced from key response elements as
Purα levels increase over the course of brain development (Muralidharan et al.,
1997). Of additional relevance is the cell cycle-dependent pattern of Purα
expression, in which nuclear levels of the protein are low in early G1 phase but
increase progressively throughout S, G2, and M-phases (Itoh et al., 1998). This
raises the possibility that Purα may play an important role in shifting the equilibrium
of the PDGF-A promoter toward a single-stranded and a more transcriptionally active
structure in proliferating cells, particularly at later stages of the cell cycle. In this
regard, Purα is a DNA unwinding protein (Darbinian et al., 2001a) with the potential
for both creating and stabilizing single-stranded conformations. It should also be
noted that Purα may also interact with a double-stranded CCAGCA motif in the ovine
placental lactogen promoter (Limesand et al., 2004). While such a motif is not
apparent in the PDGF-A promoter, the possibility that Purα may interact with doublestranded motifs in this region cannot be formally excluded.
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Figure 8. A proposed model portraying an equilibrium between the doublestranded NHE bound by Sp1 (left) and the single-stranded condition, stabilized
via binding of Purα dimers and a hypothetical C-strand binding protein (CSBP; right). The Sp1-bound, double-stranded state is shown to impart moderate
transcriptional tone while the Purα-bound, single-stranded condition provides high
transcriptional activity. The CS-BP is presented in light of a similar model described
for the MCAT enhancer of the vascular smooth muscle α-actin (SMA) gene (Kelm et
al., 1997).
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Purα is a transcription-enhancing factor in the context of the PDGF-A promoter,
consistent with its interactions with regulatory elements in promoters of such genes
as myelin basic protein, neuron-specific FE65, and neuronal nicotinic acetylcholine
receptor (nAchR). In the current study, Purα failed to augment the silencer activity of
the 5′SHS element, in contrast with its high affinity for the G-rich strand of the 5′SHS
sequence in vitro. This observation also contrasts with the silencer promoting activity
of Purα in its interactions with the muscle-specific MCAT enhancer in the vascular
smooth muscle α-actin gene (Kelm et al., 1997). The apparent lack of functional
interaction between Purα and the 5′SHS silencer could be the result of competition
with other silencing factors with greater affinity and/or abundance in the HepG2 cells
studies.
The use of MEFs derived from Purα knockout mice yielded the observation that
Purα expression was necessary for optimal expression of PDGF-A mRNA, at least in
the MEF system. Close inspection of the NHE region of the mouse PDGF-A
promoter reveals the presence of at least three GGN motifs within close proximity of
each other (GGA GGC GGG GG GGC, analogous to −89 to −64 of the human
promoter sequence), strongly suggesting this sequence is the target of Purα action in
both the mouse and human. Although the loss of transcriptional activity resulting
from Purα gene inactivation was statistically significant, the effect was rather modest.
This is not surprising in light of the abundance of Sp1 proteins in mammalian cells,
with which Purα may be competing for access to the NHE region in wild-type MEFs.
Another potential attenuating factor is the aforementioned cell cycle-dependent
pattern of Purα expression. The contribution of Purα to PDGF-A gene transcription
and steady-state concentrations of PDGF-A mRNA might only be exerted transiently
at the late stages (late S, M) of the cell cycle.
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Our current model describes a competitive scenario between Purα and Sp1 for
access to the NHE. However, Purα and Sp1 have also been shown to associate
physically and collaborate functionally in the activation of the MB1 regulatory
element of the MBP gene in mouse brain (Tretiakova et al., 1999). This interaction
was proposed to require the phosphorylated form of Sp1, whose levels are
developmentally regulated and increase over the course of brain development.
Moreover, Purα and Sp1 function cooperatively to activate transcription of the CD11c
gene during PMA-induced monocytic differentiation in U937 cells (Shelley et al.,
2002). Thus, the potential for functional collaboration between these transcription
factors at the NHE must also be considered, although an underlying mechanism that
could accommodate the presence of both factors at the same site is obscure at
present. One plausible notion is that phosphorylated Sp1 provides the initial
interaction with double-stranded DNA, followed by recruitment of Purα via protein–
protein interactions, Purα-mediated DNA unwinding, and either displacement of Sp1
or cooperative recruitment of transcriptional coactivators by both factors. The NHE is
currently being employed for testing of this complex molecular model.
The demonstration that Purα is a positive transcriptional regulator of PDGF
expression, the latter a long-recognized contributor to oncogenic transformation and
neovascularization, represents an important addition to the known roles of Purα in
cell cycle control and oncogenesis (see review, Johnson, 2003). For example,
Purα associates

with

a

number

of

cell

cycle

control

proteins,

including

hypophosphorylated retinoblastoma protein, cyclin A (Itoh et al., 1998) and CDK2 in
S-phase (Barr and Johnson, 2001), cyclin B1 in M-phase (Barr and Johnson, 2001),
and CDK5 (Gilden and ter Meulen, 2002). Our observed enhancement of a tumorpromoting mechanism contrasts with most reports to date, however, which suggest
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Purα may serve tumor-suppressor-like functions. Purα opposes growth colony
formation in K-ras transformed cells (Barr and Johnson, 2001) and other tumor cell
types (Darbinian et al., 2001b). An anti-oncogenic role of Purα in human cancer per
se is suggested strongly by its downregulation in CML patients at diagnosis
(Bruchova et al., 2002), and the frequent deletion of the PURA locus in
myelodysplastic syndrome, a condition that often precedes AML (Lezon-Geyda et
al., 2001). On the other hand, Purγ was recently shown to be upregulated in all
members of a tumor tissue panel, suggesting at least this isoform may have tumorpromoting functions (Liu and Johnson, 2002). Addition of PDGF-A to the list of genes
upregulated by Purα suggests the role of Purα in cancer may be more complex than
indicated initially. Studies to further examine the potential Purα−PDGF axis of
cellular transformation appear to be warranted.
Our lab’s previous data showed transient transfection analyses in HepG2 cells
revealed that both NM23-H1 and -H2 repressed transcriptional activity driven by the
PDGF-A basal promoter (-82 to +8). Activity of the negative regulatory region (-1853
to -883), which contains the 5’-SHS, was also inhibited modestly by NM23-H1 and
NM23-H2, indicating the role for NM23 proteins in repressing transcription of a
growth factor oncogene, providing a possible molecular mechanism to explain their
metastasis-suppressing effects. In these current experiments, we only tested a
minimum transcriptional downregulation of PDGF-A chain by NM23-H1 either
binding to 5’SHS (negative regulatory element) or NHE (positive basal regulatory
element). Compared with the basal transcriptional regulation, there is no significant
difference between two of them. When NM23-H1 cotransfected with Pura or YB-1
(single-stranded DNA binding proteins), their transcriptional regulation function on
PDGF-A chain couldn’t be changed by NM23-H1 overexpression. This suggests that
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transcriptional downregulation of NM23 on PDGF-A chain is very weak. Considering
the strong metastasis suppression of NM23, this theory of transcriptional repression
of oncogene is not ideal. So, we need a new model to explain the metastasis
suppressor function of NM23.
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CHAPTER THREE
DNA DAMAGING AGENTS CAUSE THE ACCUMULATION OF NM23 PROTEINS IN
NUCLEAR FOCI, SUGGESTING A ROLE IN DNA REPAIR

3.1. Introduction
Our current data in this project suggests that only minimum transcriptional
downregulation on PDGF-A chain promoter comes from NM23-H1. Thus, the potent
metastasis suppressor activity of NM23 would appear to be mediated via some other
function of the molecule. A potential candidate is the 3’-5’exonuclease of NM23-H1
discovered in our lab (Ma et al., 2004) and nuclease of NM23-H2 (Postel et al., 2000).
In NM23-H2, lysine-12, a phylogenetically conserved residue, was identified as the
amino acid forming the covalent complex with DNA, and critical for the cleavage of the
DNA phosphodiester backbone. It is also known that lysine-12 lies in the catalytic
pocket, essentially involved in the NDP kinase phosphorylation reaction. These
findings suggest catalysis of DNA cleavage and phosphorylation of nucleotides by
NM23/NDPK share a single active site, implying a DNA repair function (Postel et al.,
2000).
As a multifunctional enzyme, NM23 is distributed ubiquitously, though its
expression may vary in a differentiation- and tissue-specific manner. The proteins are
found both in the cytoplasm and in the nucleus (Rosengard et al., 1989). In case of
stress, such as virus infection, T lymphocyte attack, or ATP depletion, cytoplasmic
NM23s translocate into the nucleus alone or in combination with other proteins. NM23H1 is predominantly localized in the cytoplasm of Epstein-Barr virus (EBV)-negative Blymphocytes (Subramanian et al., 2001). However, in cells that are transfected with
EBNA-3C, the viral oncoprotein of EBV, NM23-H1 signals were pronounced in the
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nucleus and colocalized with EBNA-3C. In the nucleus, EBNA-3C reverses the NM23H1 mediated suppression of tumor cell migration. These observations indicate that
NM23 could sense the viral infection and translocate into the nucleus and lose its
function of suppression of tumor cell migration.
Recently, NM23-H1 was found as one component of an ER-associated complex
containing PP32 and the granzyme A substrates SET, HMG-2, and Ape1 (Fan et al.,
2003). NM23 could sense the cellular changes in tumor cells and translocate into
nucleus, nicking DNA and inducing caspase-independent apoptosis. When K562 cells
are loading with perforin and granzyme, which are cytolytic proteins released from
cytotoxic T lymphocytes (CTL) and NK cells, NM23-H1 is released from cytoplasm.
Then released NM23-H1 translocates to the nucleus, and induces DNA singlestranded nicks. All these results suggest that NM23 may also function as a stress or
energy sensor, sensing any cytoplasmic changes caused by virus infection, ATP
depletion, or DNA damage. Translocated NM23s will either repair damaged DNA, or
induce apoptosis if the DNA damage is impossible to be repaired.
To obtain direct evidence regarding the translocation of NM23 proteins into
nucleus on DNA damage, two tumor cell lines, HepG2 and HeLa, were used and
treated with the DNA damaging agents, cisplatin and etoposide. Western blot and
immunofluorescence

were

employed

to

measure

the

localization

and

compartmentation of NM23. Also, co-localization of NM23 with Ape1 was investigated
after cells were treated with DNA damaging agents.

3.2. Materials and methods
3.2.1. Cell culture and preparation of nuclear extract
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HepG2, HeLa cells were grown at 37ºC under 5% CO2 in DMEM medium
supplemented with 5% fetal bovine serum (FBS) and 2 mM glutamine. Cells grown
to 80% confluence were used for fractionation. Each cell line was treated with
cisplatin (15 μg/ml) and etoposide (15 μg/ml) for 2 h, 4 h, and 24 h. DMSO treatment
was used as control. After cells were treated for different time period, the growth
medium was aspirated; the plate was rinsed 2 times with 5 ml ice-cold PBS and cells
removed with a teflon-coated scraper (Costar). Cell nuclear extracts were prepared
as described previously (Pines et al., 2005). Briefly, 107 cells were washed once with
phosphate-buffered saline (PBS) and resuspended in 100 μl of hypotonic lysis buffer
A [10 mM HEPES, 10 mM KCl, 0.1 mM MgCl2, 0.1 mM EDTA, 2 μg/ml leupeptin, 2
μg/ml pepstatin and 0.5 mM phenylmethylsulfonyl fluoride (PMSF), pH 7.9]. After 10
min, cells were homogenized by 10 strokes with a loose-fitting Dounce homogenizer.
Nuclei were collected by centrifugation at 500 g at 4ºC for 5 min in a microcentrifuge.
The supernatant was considered as the cytoplasmic fraction. Nuclei were then
washed three times with the same volumes of buffer A in order to minimize
cytoplasmic contamination. Nuclear proteins were extracted with 100 μl of buffer B
(10 mM HEPES, 400 mM NaCl, 1.5 mM MgCl2, 0.1 mM EDTA, 2 μg/ml leupeptin, 2
μg/ml pepstatin and 0.5 mM PMSF, pH 7.9). After incubating for 30 min at 4ºC,
samples were centrifuged at 12,000 g for 20 min at 4ºC. Nuclear extracts were then
analysed for protein concentration by Bradford assay (Bio-rad) and stored at -80ºC in
aliquots.

3.2.2. Western blot
Protein (40–50 mg/lane) was mixed with loading buffer and separated by 15%
SDS–PAGE. Protein was transferred to membrane by semidry transfer apparutus.
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Following fixation of proteins, the membrane was wetted in methanol, rinsed in
distilled water, and blocked in blocking buffer containing 5% dry nonfat milk for
overnight, NM23s was detected using a polyclonal rabbit anti-NM23 antibody (Santa
Cruz) at a final dilution of 1:100 (final concentration 2 μg/ml) for 1 h. Membranes
were then incubated with buffer containing 1:10,000 diluted goat anti-rabbit
secondary antibody conjugated to horseradish peroxidase for 1 h at room
temperature. Bound secondary antibodies were detected using chemiluminescence
for 5 min.

3.2.3. Immunofluorescence staining
HeLa Cells (1x104) were grown on 8-chamber, polystyrene vessel tissue culture
glass slide (BD) and treated with etoposide and cisplantin for different time period.
Cells were washed three times with PBS and fixed with 4% formaldehyde for 10 min.
Then cells were permeabilized with 0.3% Triton X-100 for 10 min and then
preincubated with 10% goat serum for 2 h. Cells were incubated with an anti-NM23
(Santa Cruz) polyclonal antibody overnight. Primary antibody labeling was visualized
by incubation with anti-rabbit IgG-FITC (Santa Cruz, 1:100) for 60 min. 4’,6’diamidino-2-phenylindole (DAPI) (Sigma) was used for nuclear conunterstaining.
Prepared slides were then analyzed by fluorescent microscopy. For co-localization,
anti-Ape1 antibody was used as another primary antibody, and goat-anti-mouseTexas Red was used as secondary antibody.

3.3. Results
3.3.1. NM23 translocates into the nucleus following treatment with DNA damaging
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agents
To examine whether NM23 has a role in the cellular response to DNA damage,
we

probed

its

intracellular

localization

by

western

blot

and

indirect

immunofluorescence. After HeLa cells were exposured to cisplatin and etoposide for
different time course, nuclear extract was obtained and western blot analysis was
performed. Both anti-cancer reagents induced nuclear translocation of NM23
compared with untreated cells (DMSO control). It seems that cisplatin induces
nuclear tanslocation of NM23 faster (peak time is at 2 hour of treatment) than
etoposide (peak time is at 4 hour of treatment) (Figure 9A). To verify the results from
western blot of nuclear extract, indirect immunofluorescence and confocal analysis
were performed on both cell lines treated by etoposide. Immunofluorescence
microscopy (Figure 9B) and confocal microscopy (Figure 9C) results are all
consistent with western blot with peak time of nuclear NM23 increasing at 4 h of
treatment. Obviously, increase of nuclear NM23 is after its increase in the cytoplasm,
suggesting that both neosynthesis and nuclear translocation of NM23 take place at
the time of DNA damage.
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Figure 9. Cisplatin- and etoposide-induced expression of NM23 and
translocation from the cytoplasm to the nucleus. (A) Cells were cultured in
DMEM and treated with cisplatin and etoposide (15 μg/ml) for the indicated times.
Western blot analysis, performed as described in materials and methods, of NM23
expression levels of nuclear extract is indicated. DMSO, solvent for cisplantin and
etoposide, was used as control treatment. (B) Hela cells were grown on 8-well
chamber slides and treated with etoposide (15 μg/ml) for the indicated times. Cells
were then fixed, permeabilized, and stained for NM23 (green). Nuclei were
conterstained by DAPI (blue). Immunofluorescence microscopy was used for
visualization. (C) HepG2 cells were grown on 8-well chamber slides and treated with
etoposide (15 μg/ml) for the indicated times. Cells were then fixed, permeabilized,
and stained for NM23. Confocal microscopy was used for image analysis.

A.
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3.3.2. DNA damaging agents induces the concentration of NM23 within nuclear foci
Inhibition of the topoisomerase II function can result in DNA double-strand breaks
(DSBs) and, thus, lead to chromosomal translocations. DSBs must be recognized and
be able to promote the recruitment of some DNA repair proteins to the damaged sites
in order to initiate repair (Kantidze et al., 2006). To clarify the question we have
checked whether the exposure of cells to etoposide triggers the formation of NM23
nuclear foci, which so far have been taken as an indicator for the presence of DNA
repair (Raderschall et al., 1999 and Robinson et al., 2005). In untreated HeLa cells,
NM23 showed diffuse staining of the cytoplasm and nuclei (Figure 9C, DMSO
treatment). After exposure to DNA damage reagents etoposide for 4h and 24 h,
NM23s relocalized to distinct nuclear foci (Figure 10). We propose that these foci
represent sites of processing of DNA double-strand breaks (DSBs).
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Figure 10. Etoposide induces nuclear foci formation of NM23. HeLa cells were
grown on 8-well chamber slides and treated with etoposide (15 µg/ml). Cells were
fixed, permeabilized, and stained with anti-NM23 polycolonal antibody (Sigma, 1:100
dilution) and FITC conjugated secondary antibody. Immunofluorescence microscopy
was used for visualization.
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3.3.3. NM23 does not co-localize with Ape1 in response to DNA damage
To further investigate the molecular relationship between NM23 and Ape1 after
DNA damage, we examined whether NM23s co-localized with Ape1, which has been
reported to co-translocate into nucleus with NM23s in response to Granzyme A loading
or CTL attack (Fan et al., 2003). Ape1 is Apurinic apyrimidinic endonuclease redox
effector factor-1 (APE1/Ref-1) involved both in the base excision repair (BER) of DNA
lesions and in the eukaryotic transcriptional regulation (Pines et al., 2005). After cells
were treated with etoposide for 4 h and 24 h, cells were stained with anti-NM23
(green) and Ape1/Ref-1 (red). Both protein expressions were induced by etoposide
treatment, and nuclear foci were formed at 4 h and 24 h treatment. In contrast to
previous report that both proteins are in the cytoplasm, most Ape1 was found in the
nucleus even before the etoposide treatment. Four hour treatment induced more Ape1
expression in the nucleus and translocation of NM23 only. But NM23 foci do not colocalize with Ape1 foci. After 24 h of treatment, even though NM23 expression are still
high in the nucleus and foci are very significant, Ape1 staining and foci are lost in
some cells which still contain NM23 foci (Figure 11). All these data suggest that in
response to different DNA damage, NM23 and Ape1 might react differently. They may
localize to their own binding sites to initiate DNA repair and function for different time
periods.
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Figure 11. Etoposide induces NM23 and Ape1 foci that do not co-localize. HeLa
cells treated with etoposide for indicated time. After fixation, cells were stained and
examined by immunofluorescence microscopy. NM23 was visualized with FITCconjugated antibody (green) and Ape1 was visualized using a Texas red (TR)conjugated secondary antibody (red). No colocalization (yellow) was seen when
images of NM23 (green) and Ape1 (red) were merged. FITC is shown at left, TR
staining red in the middle, and the merged image at right.
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Merge

3.4. Discussion
Etoposide and cisplatin are both clinically widely used anti-cancer drugs. Cisplatin
is used in the treatment of several types of cancer and is particularly effective against
testicular tumors. Cisplatin introduces cytotoxic DNA damage predominantly in the
form of intrastrand crosslinks between adjacent purines (Yamada et al., 1997).
Etoposide specifically inhibits topoisomerase II (Topo II). It acts after cleavage of DNA
by Topo II, leaving a lesion in which the enzyme is covalently linked to 5'-ends
whereas 3' termini are free. These lesions likely develop into double-strand breaks and
single-strand DNA gaps. As a consequence, etoposide triggers checkpoint activation
(Rossi et al., 2006). Cell cycle checkpoints are regulatory pathways that control the
order and timing of cell cycle transitions and ensure that critical events such as DNA
replication and chromosome segregation are completed with high fidelity. In addition,
checkpoints respond to damage by arresting the cell cycle to provide time for repair
and by inducing transcription of genes that facilitate repair (reviewed in Elledge, 1996;
reviewed in Weinert, 1998).
One hallmark of the DNA damage response is the aggregation of multiprotein
complexes into foci or repair centers. A large amount of evidence showed that many
DNA repair proteins, such as P53 (Al Rashid et al., 2005), PCNA (Essers et al., 2005),
Rad 51 (Tarsounas et al., 2003), MRN complex (Mre11, Rad50 and NBS1) (Stracker
et al., 2002), accumulate at the DNA damage site to form nuclear foci. NM23s have
been reported to be distributed broadly in the cell in a differentiation and tissue specific
manner. The proteins are found in the cytoplasm, in mitochondria, and in the nucleus.
Our western blot and immunoflurescence results suggested that NM23s mostly exist in
the cytoplasm. If NM23s play an important role in DNA repair, they should go into
nucleus and accumulate at the DNA damage site, either alone or with other DNA
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repair proteins. In the current study, as shown in western blot, NM23 expression is
induced dramatically in two tumor cell line (HepG2, HeLa) in response to etoposide
and cisplatin treatment. Cisplatin elicits peak translocation within 2 h of treatment,
while etoposide induces nuclear translocation peak at 4 h of treatment, suggesting
different repair responses induced by two different chemical reagents. But both
treatments cause NM23 expression returning to near baseline levels by 24 h.
Immunofluorescence studies in Hela cells confirm the immunoblot results and
demonstrate increased expression and nuclear translocation of NM23 during periods
of genomic stress. Furthermore, distinct nuclear foci were demonstrated in the cells
following exposure to DNA damaging agents. Taken together, these results strongly
suggest the DNA repair function of NM23s in the DNA damage response.
More studies are actively underway to investigate the potential role of NM23 in
DNA repair and physical interactions between H1 and other repair proteins. More DNA
damaging treatments are employed in our lab to explore the repair mechanisms of
NM23. In fact, we have observed that UV irradiation appears to induce NM23-H1
expression and localization in nuclear foci to an even greater extent than etoposide
and cispatin. Moreover, NM23-H1 containing foci appear to colocalize with Rad1, a
component of the 9-1-1 complex (Rad9, Rad1, and Hus1) implicated DNA damage
induced by UV and other agents.
NM23 and Ape1 have been described as two components of the SET complex
in the cytoplasm (Fan et al., 2003). Other reports have described that Ape1 is found
in the cytoplasm at a significant level when determined by immunocytochemistry with
anti-Ape1 antibodies (Ramana et al., 1998 and Kakolyris et al., 1999). Our results
are consistent with the earlier report (Takao et al., 1998), in that Ape1 molecules
were exclusively present in the nuclei. Four hour of etoposide treatment induces
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significantly increased expression of Ape1 in the nucleus, and those foci formed after
etoposide treatment seem to be much larger than NM23 foci in the same cells.
Almost no NM23 foci and Ape1 foci colocalize. At the time point of 24 h treatment,
some cells lost staining of Ape1, but NM23 foci are still contained in the nucleus,
suggesting different functioning time in the process of DNA repair. All these data
suggest that, even though the NM23, as an exonuclease, and Ape1, as an
endonuclease, participate DNA repair, their interaction may be limited to responses
to specific types of lesions.
The isoform of NM23s in this current study could not be determined because
the antibodies used in immunoblot and immunofluorescence studies cross-react to
both NM23-H1 and H2. More specific anti-NM23-H1 antibody should be used in
order to determine whether the DNA repair function is more related to NM23-H1.
While DNA repair is an obvious potential function of the 3’-5’ EXO activity,
another outcome of cells after genomic insult, apoptosis, has to be considered. In
this regard, the study about the relationship of NM23 and apoptosis has been
performed to investigate complementary function of NM23 in our lab.

Copyright ©Qingbei Zhang 2006
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CHAPTER FOUR
THE NDPK AND, POSSIBLY, 3’-5’EXO ACTIVITIES OF NM23-H1 PLAY
IMPORTANT ROLES IN SUPPRESSING PROGRESSION OF HUMAN
MELANOMA CELLS TO A METASTATIC PHENOTYPE

4.1. Introduction
Once the hypothesis of DNA repair function of NM23 EXO activities has been
tested, we will test for the first time the extent to which exonuclease activities, and by
extension, the repair activities of H1 are required for the ability to suppress tumor
metastasis. In the cell culture models for studying antimetastatic activities of NM23
proteins, melanoma is a highly suitable cell to establish the study model. Because,
first, the metastasis suppressor function of NM23-H1 was identified in melanoma
cells (Steeg et al., 1988). Second, melanoma is highly metastatic compared with
another two skin cancers, basal cell cancer and squamous cell cancer. Although
representing only approximately 4% of skin cancers, melanoma accounts for
approximately 79% of skin cancer deaths, with an annual mortality of 2.3 per
100,000 people. Third, clinical data indicates a reverse correlation between NM23
expression in primary melanomas and rate of progression to metastasis (Florenes et
al., 1992). Last, there is the availability of a panel of melanoma cell lines, developed
and characterized in the laboratory of M.Herlyn (Wistar Inst), that represent different
stages of progression (Herlyn et al., 1985) and can be used for the study of NM23 in
impairing progression of melanoma cells and suppression of metastasis.
Clinical and histologic studies have resulted in defining five major steps of
melanoma development and progression (Figure 12). Step 1, common acquired and
congenital nevi with structurally normal melanocytes; step 2, dysplastic nevi with
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structural

and

architectural

atypia;

step

3,

RGP

(radial

growth

phase),

nontumorigenic primary melanomas without metastatic competence, corresponding
to this early stage of horizontally spreading growth in the epidermal and papillary
dermal layers of skin; step 4, VGP (vertical growth phase), tumorigenic primary
melanomas with competence for metastasis, representing a more progressed and
invasive stage characterized by aggressive downward invasion into dermal layer and
beyond; and step 5, metastatic melanoma, which were derived either from metastatic
lesions or by repeated passaging of tumor explants of prematastatic lines in rodents
(Herlyn et al., 1985). It is now appreciated that transformation of melanocytes into
malignant melanoma involves the interplay between genetic factors, UV exposure,
and the tumor microenvironment.
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Figure 12. Process of melanoma development from normal melanocytes. Nevi
are characterized by aberrant cell growth, consisting of enlarged, coalescent nests of
nevocytes, which display different degrees of cytologic dysplasia. Further
progression results in malignant cells, which grow only within or in close proximity to
the epidermis (radial growth phase; RGP). Eventually, cells acquire the ability to
invade deeply into dermis (vertical growth phase; VGP) and then into lymphatics and
blood vessels, leading to systemic dissemination (metastatic melanoma). BM,
basement membrane (Graphic is from http:// www.wistar.upenn.edu/herlyn/default).
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Over 18 years of intensive study, multiple enzymatic activities of NM23-H1 have
been uncovered. But the molecular mechanisms underlying its anti-metastatic activity
remains controversial. To date, the strongest case for metastasis-suppressing activity
has been made for the hisK of NM23-H1. Some evidence demonstrated that hisK null
mutants of NM23-H1 (such as P96S and S120G) lose some of the motility-suppressing
activity of the wild-type protein when overexpressed in MDA-MB-435 breast carcinoma
cells (Freije et al., 1997; Wagner et al., 1997). However, definitive validation of the role
played by the hisK awaits detailed characterization of relevant downstream hisK
substrates and their relationships to metastasis suppression. Other data indicated that
there is no correlation between NDPK activity and suppression of tumor metastatic
potential among control and NM23-H1 transfected murine melanoma cells (MacDonald
et al., 1993). This has yet to be demonstrated using the forced expression model used
above due to lethality associated with overexpression of NDPK mutants.
3’-5’ exonuclease activity is a newly identified biochemical function of NM23-H1 in
our lab (Ma et al., 2004). This activity is very intriguing in light of the association of
these enzymes with DNA repair processes, and the mutator phenotype which often
arises as a consequence of their deficiencies (reviewed in Shevelev and Hübescher,
2002). To overcome numerous barriers in the whole metastasis process, tumor cells
must acquire enough genetic alterations which are usually caused by accumulation of
mutations. So, a primary working hypothesis of this current project is that 3’-5’ EXO
activity plays a major role in metastasis suppressor function of NM23-H1 molecule.
Loss of NM23 could lead to accumulation of mutation and thus progression to the
metastatic phenotype. This hypothesis does not exclude contributions from NDPK and
hisK activities of NM23-H1 to the metastatic process. In fact, this highly selective and
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low efficient process could be completed by combination of multiple functions of
metastasis suppressor.
To study the relevance of EXO or possibly other enzymatic activities to
metastasis suppression, two melanoma cell lines were selected because of their
abnormally low amount of NM23-H1 and NM23-H2 expression. WM793, a VGP cell
line, represents a premetastatic cell line, while 1205LU, a MET cell line, represents
metastatic cell line. After stable transfection and fluorescence-activated cell sorting, all
the transfected cell lines are expressing equal amount of wild-type or variant mutant
NM23-H1, including H118F mutant which was previously reported lethal to cells, was
successfully transfected into both 1205LU and WM793 cells. These cell lines were
used to measure the metastatic characteristics both in cell culture (motility assay,
invasion assay) and in vivo, using standard approaches of experimental and
spontaneous metastasis. Relevance of an enzymatic activity to suppression of
metastasis should be apparent through a significant reduction in the antimetastatic
activity of its corresponding mutant. The relevance of enzymatic activities of NM23-H1
to prevention of tumor progression in premetastatic WM793 cells was also tested.
Motility assay and invasion assay are most widely used in vitro methods to study
cell migration and the effect of various chemoattractants. These assays are largely
based on the use of Boyden chambers or Transwell culture inserts in which porous
membranes separate seeded cells from a chemotactic factor supplied in the medium
in the lower chamber (de la Monte et al., 2002). Matrigel is considered as in vitro
counterpart of basement membrane. It has been used to characterize involvement of
ECM receptors and matrix degrading enzymes which play roles in tumor progression.
But in vitro assays of invasiveness have been less than perfect. Animal models
provide a more clinically accurate mechanism to study metastasis. Spontaneous
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metastasis assay in nude mice takes about 4 months to complete. It recapitulates all
the metastatic steps; therefore it’s the best study model even though it is time
consuming. Experimental metastasis takes only 1 month. But this assay skips many
early steps of metastasis and starts from survival of cells in blood stream (see Figure
1).
Based on definition, metastasis suppressor genes differ from tumor suppressor
genes by which transfection of metastasis suppressor gene back to cells has no effect
on cell proliferation, colony formation in soft agar, and primary tumor growth. Cell
proliferation rate was determined by MTS assay in the current project. It’s very
important to know the growth rate of all parent cells and transfected cells. Because the
tested cells stayed in animal model in such a long time, similar growth rate of all the
cell lines won’t have any effect on metastasis assay.

4.2. Materials and methods
4.2.1. Cell culture, whole cell extract, and western blot
Melanoma cell lines were cultured in MCDB153/L15 (Sigma) medium (v/v: 4/1)
supplemented with CaCl2 (2 mM), insulin (5 mg/ml) and 2% fetal bovine serum (FBS)
(Gibco). At confluence, cells were centrifuged at 500 g for 5 min at 4ºC and
supernatant was discarded. The cell pellet was loosened by gently vortexing for 5 s
followed by addition of equal volume of M-Per (Pierce) with vigorous shaking. After
incubation in 4ºC overnight, an aliquot was examined under a microscope to ensure
that cells had uniformly lysed. The supernatant was aspirated after spinning for 30
min at maximum speed at 4ºC. The protein concentration was measured by Bradford
assay (BioRad). Protein (40-50 mg/lane) was mixed with loading buffer and
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separated by 15% SDS-PAGE. Protein was transferred to a nitrocellulose membrane
by a semidry transfer apparatus. NM23s was detected using a polycolonal antiNDPK antibody (Lab vision) at a final dilution of 1:500 for 1 h, and goat anti-rabbit
secondary antibody conjugated to HRP for 1 h at room temperature. Bound
secondary antibodies were detected using chemiluminescence (Amersham) for 5
min.

4.2.2. Plasmid construction, stable transfection, and flow cytometry
Wild-type and variant mutant NM23-H1 cDNA were cloned into the pCI vector.
Other features in this vector include CMV promoter, green fluorescence protein
(GFP) cDNA, and an internal ribosome entry sequence (IRES) interposed between
the cDNAs to permit cotranslation of NM23-H1 and GFP from a bicistronic mRNA.
Melanoma cells were seeded in six-well plates with 2 x 105 cells/well. Cells at a
confluence of 70% were incubated with DNA (wt or mutant NM23-H1 cDNA) and
Fugene 6 (Roche) complex (3:1 ratio) for 48 h at 37ºC. pSV2Neo was cotransfected
as a selection marker. After 48 h incubation, cells were split in a 1:4 ratio to 100 mm
dishes. Twenty-four later, geneticin (G418, Life technologies; 250 µg/ml) was added
for selection. After 4 weeks selection, all the cell colones were trypsinized and
pooled together. Cells were sorted by fluorescence-activated cell sorting (FACS)
using a FACS Calibur flow cytometer. The sorting procedure has yielded more than
95% GFP fluorescent cells (Figure 13).
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Figure 13. Procedures of stable transfection of melanoma cells.
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4.2.3. Two-dimentional gel electrophoresis
Materials for the first and second dimension were obtained from Bio-Rad.
Approximately 50 μg of purified proteins and whole cell extracts from transfected
1205Lu cells were loaded in 350 μl of rehydration buffer containing 8 M urea, 4%
CHAPS, 100mM DTT, 0.2% Bio-lytes, and 0.001% bromophenol blue. ReadyStrip
IPG strips (17 cm, PH 4-7) were placed side down into the rehydration buffer in a
tray channel with 3 ml of mineral oil applied on the top. Rehydration was carried out
for 12 h at 50 volts. The first dimension of electrophoresis was run in a Protean IEF
cell, according to the manufacturer's instructions. To solubilize focused proteins and
allow SDS binding, IPG strips were equilibrated prior to second dimension
electrophoresis with 375 mM Tris–HCl, pH 8.8, 6 M urea, 2% SDS, 2% DTT, 20%
glycerol for 10 min to reduce sulfhydryl groups, followed by 375 mM Tris–HCl, pH
8.8, 6 M urea, 2% SDS, 2% iodoacetamide, 20% glycerol for an additional 10 min
period to alkylate sulfhydryl groups. Second dimension electrophoresis was
performed in 15% acrylamide gels. Then western blot was performed as previously
described.

4.2.4. Motility assay
Transwell 24-well plates (6.5 mm diameter, 8.0 μm pore size) (Corning Inc, Life
Sciences) were incubated at 37ºC overnight before 1x104 melanoma cells (in 0.1 ml
of medium) were plated in the upper compartment. The lower compartment was
loaded with 0.6 ml of medium plus 10% FBS as chemoattractant. After 24 h of
incubation at 37ºC, non-invading cells in the upper compartment were removed with
a cotton swab. The microporous membrane was fixed in 70% ethanol for 1 h and
cells reaching the membrane surface of the lower compartment were stained with
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hematoxylin for 2 h. Stained cells were counted using an inverted light microscope.
Five random high power fields (10x10) were counted to get an average number for
one well. The experiments were repeated in triplicate wells for at least three times.

4.2.5. MTS assay
Cell viability was assessed with the nonradioactive cell proliferation 3-(4,5dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) assay using CellTiter96 AQueous Reagent (Promega) as described by the
manufacturer. Briefly, cells were cultured in 96-well plates at a concentration of 2 x
103/well. On day 1, day 2, day 3, day 4, and day 5, 20 µL of CellTiter96 AQueous
Reagent (MTS/PMS mixture solution) were added into each well of 96-well plate
containing 100 µL of cells in culture medium. Then the plate was incubated for 1 hour
at 37°C, 5% CO2, and formazan absorbance was measured at 490 nm on a ELISA
plate reader. Each measurement was done in triplicate and the mean value was
calculated.

4.2.6. Soft agar assay
For anchorage-independent growth, 5x104 parent and transfected cells were
resuspended in 3 ml of growth medium containing 0.3% Nobel agar and plated on
each well of 6-well plate containing a solidified bottom layer made of 1% Nobel agar in
medium. After the 0.3% Nobel agar solidified, 2 ml of growth medium was added to the
plates and replaced every 3 days. 28 days after plating, colonies were stained with
crystal violet (0.005%) and imaged at 10X magnification. Each experiment was
performed in triplicate and the mean value was calculated.
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4.2.7. Invasion assay
BD BioCoatTM MatrigelTM invasion chamber (24-well format) were incubated at
37ºC overnight before 1x104 melanoma cells (in 0.1 ml of medium) were plated in the
upper compartment. The lower compartment was loaded with 0.6 ml of medium plus
10% FBS as chemoattractant. After 24 h of incubation at 37ºC, non-invading cells in
the upper compartment were removed with a cotton swab. The microporous
membrane was fixed in 70% ethanol for 1 h and cells reaching the membrane
surface of the lower compartment were stained with hematoxylin for 2 h. Stained
cells were counted using an inverted light microscope. Five random high power fields
(10x10) were counted to get an average number for one well. The experiments were
repeated in triplicate wells for at least three times. The standard error of the mean
was

calculated

from

independently performed

experiments.

The

statistical

significance of the data was analyzed using the Student t test.

4.2.8. Progression of WM793 in protein-free medium
This is a modified method from development of invasive and growth factorindependent cell variants from primary human melanomas (Kath et al., 1991). WM793
parent and transfected cells were plated at high density (2x104) in 24-well plates
precoated with 0.1% gelatin in serum free medium. After 1 week adaptation, cells were
trypsinized and reseeded at low density (1000 cells/well of 6-well plate). Two months
later, colonies formed in each well from each cell line were counted, and then pooled
and replated in the protein free medium at low density for next passage. Total 4
passages were performed. Results were expressed as the % colony formation
efficiency (# of colony yield per 1000 seeded cells) at each selection cycle (Figure 14).
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Figure 14. Progression of premetastatic melanoma cells in protein-free medium.
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4.2.9. In vivo metastasis assays
Care of mice, surgery and injection protocols were approved by the IACUC at
the University of Kentucky Medical Center (protocol # 00319M2001 and
00801M2004) and followed the National Institutes of Health guidelines. To produce
spontaneous lung metastasis, a total of 2 million 1205LU parent or transfected cells
in 200 μl HBSS were injected subcutaneously into the flank of athymic nude mice
(Harlan, nu/nu) using a 1 ml tuberculin syringe. Tumor volumes were recorded every
3 days from two-dimensional measurements obtained with vernier calipers, using a
standard formula (Tomayko and Reynolds, 1989). After 28 days, when tumors reach
800 mm3 (~1 cm diameter), mice were anathesized under isofluorene and primary
tumors were removed and checked for fluorescence (Kodak Image Station 4000).
Nude mice were kept for another 3 months to permit metastatic growth. At the end of
the experimental period, mice were euthanatized and lung metastasis was
determined by counting metastatic nodules under a dissection microscope. Freshly
dissected lungs were mounted in OCT (Tissue Tek) and frozen in a bath of liqud
nitrogen. A total of 10 μm lung sections were obtained using a cryo-microtome (Leica
3050S) and were mounted onto glass slides (Super Frost Plus, Fisher). All the slides
were stained by H.E. staining. Photographs were taken at

10 and

20

magnification. To produce experimental lung metastasis, 2x106 cells were injected
directly into the lateral tail vein as described previously (Kath et al., 1991). Lungs
were scored for metastasis nodules and frozen for section as described above
(Figure 15).
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Figure 15. Illustration of procedures of in vivo metastasis assays. In
spontaneous metastasis assay, 2x106 1205LU parent or transfected cells were
injected subcutaneously. After one month, the primary tumors were removed and
mice were kept alive for another three months to let lung metastases formed. At the
end of the experiment, mice were sacrificed and lung nodules were counted. In
experimental metastasis assay, 2x106 1205LU parent or transfected cells were
injected through tail vein, and lung nodules were counted after one month (graphics
from Minn et al., 2005).

Spontaneous Metastasis

3 months

1 month

Experimental Metastasis
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4.3. Results
4.3.1. Expression of NM23-H1 and NM23-H2 is frequently lost in many metastatic
melanoma cell lines
A panel of melanoma cells, including different stages of RGP, VGP, and MET,
was screened by immunoblot for NM23 expression. A significant loss of expression
for both NM23-H1 and NM23-H2 has been demonstrated in five out of seven total
MET cell lines (Figure 16). Another two MET cell lines, WM164 and 451LU, are
demonstrated marked expression of NM23-H1 and NM23-H2, suggesting the
multifunctional enzymatic activities of NM23s instead of metastasis suppression.
Interestingly, WM793, a cell line from VGP group, was also found the total loss of
NM23-H1 and H2 expression, suggesting the potential malignancy and invasiveness
of this cell line. Two cell lines were employed for overexpressing wild-type or mutant
NM23-H1 by stable transfection due to their very low expression of endogenous
NM23s. 1205LU from MET represents highly metastatic melanoma cells, and
WM793 from VGP represents premetastatic models of melanoma. 1205LU cells
were originally derived from WM793 cells in animal models. Forced expression of
wild-type and mutant NM23-H1 in these two cell lines provides useful tools to
determine the extent to which each of the enzymatic activities of NM23-H1, the 3’-5’
EXO in particular, suppresses metastatic progression.
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Figure 16. Expression of NM23-H1 and H2 in melanoma cell lines. Whole cell
extract from each melanoma cell line was obtained and 40 μg total protein was
loaded for each lane. Following SDS-PAGE gel and semidry transfer of protein,
western blot was performed by using anti-NDPK antibody (Lab vision, 1:500 dilution)
and goat-anti-rabbit secondary antibody (Pierce, 1:10,000 dilution). RGP, radial
growth phase; VGP, vertical growth phase; MET, metastatic
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4.3.2. Motility of melanoma cells is inversely correlated to the expression of NM23s
Since the expression of NM23 is related to clinical outcome of tumor patients
(Ohba et al., 2005; Wang et al., 2004; Terada et al., 2002), it is highly likely that the
expression of NM23s is also correlated with tumor cell invasiveness. To investigate
the relationship between NM23s and motility of melanoma cells, transwell motility
assay was carried out among different melanoma cell lines. As we expected, cell
motility is inversely correlated with the expression of NM23-H1 and NM23-H2. Three
MET cell line, WM1158, 1205LU, and WM239, exhibited the highest motility
compared with other melanoma cell lines, while other VGP or RGP cells
demonstrated

minimum

of

motility.

Interestingly,

451LU

from

MET

with

extraordinarily high expression of NM23 exhibited the lowest motility, suggesting
NM23 is not exclusively correlated to metastasis suppression, but highly correlated
to cell motility (Figure 17).
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Figure 17. Motility of melanoma cells is inversely correlated to the expression
of NM23s. Melanoma cells (1x104 cells per well) were plated into upper chamber of
24-well transwell plate. Cells were incubated at 37ºC for 24 h with 10% FBS in the
medium in the lower chamber as chemoattractant. Cells were removed by cotton
swab at the end of the experiment, and cells migrated through the pores of
membrane were fixed and stained with hematoxylin. Stained cells were counted
under an inverted light microscope. Five random high power fields (10x10) were
counted to get an average number for one well. The experiments were repeated in
triplicate wells for at least three times.
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4.3.3. Wild-type and variant mutant NM23-H1 are stably expressed in WM793 and
1205LU cells
Transiently transfected cells were selected by G418 (geneticin, 250 µg/ml) for
about 4 weeks. After drug selection, cell colonies are full of the whole 100 mm
dishes. Not all of those colonies are GFP-positive. Those GFP-negative colonies are
probably from G418 resistant cells, or more possibly, are from pSV2Neo only
transfected cells. Some colonies are partially green: part of cells is green, but
another part of cells in the same colony is not green, suggesting those tumor cells
are heterogeneous even under the situation of cell culture.

Some colonies are

unanimously GFP positive. The intensity of GFP is varied in different green cells,
suggesting either the difference of cDNA copy numbers in stable transfection or the
difference of transcriptional or translational level. To make sure that all the forced
expressions of NM23-H1 are at the same level, fluorescence associated cell sorting
(FACS) was employed to obtain all GFP positive cells with similar intensity of green
signal. The sorting procedures have yielded more than 95% GFP fluorescent cells
(Figure 18A and B) and intensity of GFP in each transfected cell line is at the range
of 102 to 104 compared with the non-transfected parent cells.
To further compare the protein expression in each transfected cell line, western
blot of whole cell extract from each cell was performed immediately after cell sorting
(passage 2 and passage 3). After several passages, stably transfected cells
(passage 8) were measured again for protein expression. In the early passage,
transfected cell obtained significant overexpression of NM23s compared with parent
cells. This was more obvious in WM793 cells with almost no endogenous NM23s
expressed in parent cells (Figure 18C). After several passages, 1205LU transfected
cells were demonstrated fading GFP signal under the UV microscope. So, we are
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concerned about that the transfected 1205LU cells are losing NM23 expression. But
transfected WM793 cells are very stable in showing the percentage and intensity of
green cells. To investigate whether transfected 1205LU cells are still expressing
NM23-H1 at later passage level, western blot was performed again on whole cell
extract of transfected 1205LU cells at passage 8. Different from the result of passage
3, all the mutant transfected cells demonstrated the same amount of protein
expression as parent cells while wild-type NM23-H1 transfected cells express
minimally increased proteins (Figure 18D). There are two possibilities explaining this.
It could be the transfection that is not stable enough, so cells keep losing inserted
NM23 copy. Another possibility is that NM23 expression is tightly controlled in this
cell line. So, if they are expressing mutant NM23, the cell will downregulate the
endogenous NM23 expression. Western blot could not tell between the endogenous
NM23 and mutant NM23, but 2-D gel would provide this informaton based on their
changed pI value of those mutants.
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Figure 18. Wild-type and variant mutant NM23-H1 are stably expressed in
WM793 and 1205LU cells. (A) Stably transfected WM793 cells sorted for GFP
fluorescence represent highly enriched transfectant populations. Shown is GFP
fluorescence in WM 793 cells that express wild-type or mutant variants of NM23-H1.
(B) Stably transfected 1205LU cells. (C) Western blot of whole cell extract of
transfected cells at passage 3. P, parent cell. W, wild-type. (D) Western blot of whole
cell extract of transfected 1205LU cells at passage 8.
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4.3.4. Endogenous and mutant NM23s are equally expressed in transfected 1205LU
cells
Wild-type or mutant NM23s were overexpressed in stably transfected 1205LU
cells at early passage number (P3). After several passages, the expression of NM23
went down (Figure 18D) to the level of endogenous protein level, suggesting that
NM23 expression is strictly limited to some extent. To measure the origin of the
protein expressed in transfected 1205LU cells, 2-D gel was employed to separate
the wild-type (endogenous) and all mutant NM23s. Single amino acid change causes
significant change of pI value of each mutant. Purified wild-type NM23-H1 and K12Q
mutant were run on 2-D gel to test their pI value. The K12Q mutant (theoretical pI
5.60) was separated markedly from wild-type NM23-H1 (theoretical pI 5.83) (Figure
19A). To study the persistence of forced NM23 expression in stably transfected
1205LU cells, 50 μg whole cell extract from parent cell line and three mutant
transfected cell lines were loaded and run on 2-D gel followed by western blot. In
parent cell, different from purified wild-type NM23-H1, endogenous NM23-H1 was
demonstrated as two separate dots, suggesting the existence of phosphorylated
NM23-H1. These two protein dots have been demonstrated in every mutant
transfected cell line at decreased level compared with parent cells. Furthermore, all
mutant NM23-H1s have been demonstrated in each cell line at the same expression
level of endogenous protein, indicating mutant protein and endogenous protein are
equally expressed in each mutant transfected cell lines (Figure 19 B).
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Figure 19. Mutant NM23-H1 is stably expressed in transfected 1205Lu cells. (A)
Purified wild-type NM23-H1 (3 μg) and K12Q mutant protein (6 μg) were loaded on 17
cm IPG strips. Gels were run on first dimensional and secondary dimensional gel as
described in methods. Proteins were transferred to nitrocellulose membrane by
semidry methods followed by detection with western blot. (B). Whole cell extract from
1205LU cells and three transfected cell line (50 μg) was tested in the same way as
(A).
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4.3.5. Overexpression of NM23-H1 in melanoma cells has no effect on
transformation phenotype
NM23-H1 is a metastasis suppressor protein and should not have any effect on
transformation phenotype. To test whether NM23 transfection has no effect on cell
proliferation, a serial of MTS assay was performed from day 1 to day 5 on both cell
lines. Either wild-type NM23-H1 or mutant NM23-H1 transfection has no any effect
on proliferation of both cell line compared with parent cells, consistant with the
definition of metastasis suppressor gene (Figure 20A). Anchorage independent
growth assay in soft agar is considered as a stringent assay for detecting malignant
transformation of cells. Colony formation in soft agar of transfected cell lines was
compared and transfected WM793 cells showed similar colony formation ability as
parent cells. For 1205LU cells, wild-type and K12Q, H118F mutant overexpression has
no effect on anchorage independent growth in soft agar compared with parent cells.
But to our surprise, P96S mutant transfected cells had significantly decreased colony
numbers compared with other 1205LU transfected cells, suggesting adominantnegative function of this mutant (Figure 20 B).
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Figure 20. Overexpression of NM23-H1 in melanoma cells has no effect on the
transformed phenotype. (A) Cell proliferation rate was determined by MTS assay.
Cells were plated in 96-well plate from 2x103 on day 0, and were measured on day 1
to day 5. (B) Cells (5x104) were seeded in the top medium and stained by 0.005%
crystal violet for 1 h after 28 days. Colony numbers were counted by five random
high power fields to get an average number. The experiments were repeated in
triplicate wells for at least three times.
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4.3.6. Forced expression of wild-type and K12Q mutant NM23-H1 decreased motility
in 1205LU cells
Cell motility is a complex cellular function that is altered through changes in cell
adhesion and is also reflected through cellular migration (Sattler et al., 2003).
Enhanced motility is one of the characteristics of malignant cells. To determine that
the relationship between motility and NM23 as well as the contribution of enzymatic
functions of NM23-H1 to motility, transwell motility assay of parent and transfected
WM793 and 1205LU cell lines was performed. Wild-type NM23-H1 transfected cells
were expected to lower the motility of WM793 cells based on the metastasis
suppression nature of NM23-H1. Surprisingly, wild-type NM23-H1 transfected
WM793 cells as well as all the H1 mutant-transfected WM793 cells had a tendency
to enhance cell motility compared with parent cells, with significance in K12Q and
H118F mutant tranfected cell lines. For 1205LU cells, wild-type and K12Q mutant
transfected cells decreased cell motility markedly, while H118F and P96S mutant
transfected cells have no significant difference with parent cells (Figure 21).
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Figure 21. Overexpression of NM23-H1 wild-type and K12Q mutant decreases
motility in 1205LU cell. 1x104 cells were plated in upper chamber with 0.1 ml of
medium plus 2% FBS. 0.6 ml of medium plus 10% FBS was added into lower
chamber as chemoattractant. Cells were incubated at 37°C for 24 h to let cell
migrate. At the end of the experiment, non-migrated cells were removed by cotton
tips, and migrated cells were fixed and stained with hemotaxyolin for 2 h. Cells were
counted by five random high power fields to get an average number. The
experiments were repeated in triplicate wells for at least three times.
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4.3.7. NM23-H1 K12Q mutant lost invasion-suppressor activity in WM793 cell but not
in 1205LU cell
Measurement of the tumor cell invasion through a microporous membrane
coated with BD Matrigel™ Matrix in Boyden-like chambers is a widely accepted in
vitro metastasis assay. Matrigel is a reconstituted basement membrane, which
simulates the basement membrane in vivo. Degradation of these matrix membranes
is a feature of invasive cells and has been used in an attempt to understand the
process regulating critical steps of tumor cell invasion. To investigate the effect of
NM23-H1 on cell invasion activity, all the transfected WM793 and 1205LU cells were
measured for invasiveness compared with the parent cells. Inconsistant with motility
assay, wild-type, H118F mutant and P96S transfected WM793 cells all exhibited
decreased invasiveness compared with parent cells, while K12Q mutant NM23-H1
transfection lost the function of invasion suppression, suggesting exonuclease
function of NM23-H1 may play a role in malignancy and tumor progression. For
metastatic cell line 1205LU, transfection of NM23-H1 and variant mutants decrease
invasiveness of metastatic melanoma cells, consistent with the results of motility
assay. Loss of exonuclease function of NM23-H1 has no effect on invasion activity
compared with wild-type H1 and other mutant H1 (Figure 22).
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Figure 22. NM23-H1 K12Q mutant lost invasion-suppressor activity in WM793
cell but not in 1205LU cell. 1x104 cells were plated in upper chamber with 0.1 ml of
medium plus 2% FBS. 0.6 ml of medium plus 10% FBS was added into lower
chamber as chemoattractant. Cells were incubated at 37°C for 24 h to let cell invade
the matrix and migrate. At the end of the experiment, non-invaded cells were
removed by cotton tips, and invaded cells were fixed and stained with hemotaxyolin
for 2 h. Cells were counted by five random high power fields to get an average
number. The experiments were repeated in triplicate wells for at least three times.
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4.3.8. NM23-H1 impairs the progression of premetastic melanoma cell WM793 and
exonuclease and NDPK activities are all involved.
The hypothesis of the current project is that exonuclease function of NM23-H1
may play an important role in DNA repair. Loss of this function leads to accumulation
of mutations and genomic instability, and thus the progression of tumor cells.
WM793 is the early stage of 1205LU (see 5.1 introduction). There is a progression of
WM793 cells in vitro and in vivo, to become 1205LU cells. To investigate whether
replacing NM23-H1 back into WM793 cells can prevent progression of this cell line in
serum-free medium, diluted WM793 cells were plated in six-well plate with protein
free medium (w/o either serum or insulin). After 8-10 weeks, cell colony numbers
were counted and cells were pooled and replated for next cycle (as described in
methods). First, WM793 cells progressed in protein free medium. The colony
formation efficiency was about 20 out of 1000 seeded cells. This efficiency increased
to 200 out of 1000 cells by the end of fourth cycle, suggesting the WM793 cell line
progressed and became more malignant after cultured in protein free medium. Wildtype NM23-H1 significantly suppressed this progression process, ending up with less
number of colonies and smaller colony size than that of other mutant transfected
cells at 3rd and 4th cycle. But K12Q mutant (exonuclease deficient) lost the function of
suppression of cell progression. By the end of 3rd and 4th cycle, colony numbers and
size were both similar to that of parent cells and significantly increased by comparing
with wild-type H1 transfected cells. Interestingly, H118F mutant (NDPK deficient)
transfection also demonstrated the similar results as K12Q mutant by the end of 4th
cycle (similar colony size but less colony numbers) even though it has no difference
in colony number and size with wild-type H1 transfected cells by the end of 3rd cycle,
suggesting NDPK may also be involved in the suppression of tumor progression.
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Surprisingly, P96S mutant H1 (hisK deficient) prevents WM793 progression as
effectively as wild-type H1, with the least and smallest colonies formed by the end of
3rd and 4th cycle, suggesting that hisK is not associated with suppression of WM793
cell progression (Figure 23A). Summary of colony numbers of each cell line at each
cycle are shown in Figure 23B.
Since this experiment took such a long time to complete, the stability of the
overexpression level of NM23-H1 and variant mutants was concerned. To test the
consistency of GFP expression in each transfected WM793 cells, 30 colonies from
each transfected cell line were counted to compare the ratio of GFP-positive and
GFP-negative colonies. The result showed that wild-type, K12Q and P96S H1
transfected cells kept consistent GFP expression, with only small fraction of colonies
with GFP expression lost. H118F H1-transfected cells were somewhat less stable,
but 50% of its colonies retained detectable GFP expression (Table 1).
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Figure 23. The NDPK, and possibly, 3’-5’exonuclease activities of NM23-H1 are
associated with suppression of progression of premetastatic WM793
melanoma cells to a growth factor-independent phenotype. (A) After adapted in
serum-free medium at high density for 1 week, cells were plated at low density in
protein free medium (serum free medium plus no insulin). Each cycle took about 810 weeks. Colony numbers were counted as colony formation efficiency at the end of
each cycle, and cells were pooled and replated for the next cycle. Representive
formed colonies from each cell line were fixed with 4% formaldehyde and stained
with 0.005% crystal violet. (B) Summary of colony formation efficiency of each cell
line at each cycle.
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Table 1. Expression of heterologous gene products is maintained for the
WM793 cell panel over the course of four cycles of selection in protein-free
culture medium. A total of 30 colonies from each cell line were counted.
GFP+

GFP-

WM793-WT

21

9

WM793-K12Q

25

5

WM793-H118F

15

15

WM793-P96S

25

5
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4.3.9. Wild-type and P96S NM23-H1 suppress spontaneous lung metastasis of
1205LU cells while K12Q and H118F mutant H1 lost metastasis suppressor activity
In vitro metastasis assays test only one or two characteristics of metastatic
tumor cells. In vivo models provide a more clinically accurate mechanism for
studying tumor development and progression. To determine which enzymatic
function of NM23-H1 is associated with metastasis suppression, spontaneous lung
metastasis of 1205LU was performed on athymic nude mice. 2x106 parent and
transfected 1205LU cells were injected subcutaneously on the left flank of each
mouse. Four weeks later, when skin primary tumor volume reached 0.8-1.0 cm3,
tumors were removed and mice were kept for another 3 months for lung metastases
formation. Removed tumors were scanned with Kodak Image Station 4000 for GFP
expression. Generally, the primary tumor grew at the same rate, suggesting that
transfection of wild-type H1 and mutant H1 into 1205LU has no effect on primary
tumor growth, consistent with the definition of metastasis suppressor gene. K12Q
mutant H1 transfected tumor cells grew a little slower. But the primary tumors in this
group reached 0.8 cm3 5 days later and excised at that time (Figure 24).
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Figure 24. Transfection of wild-type and mutant H1 has no effect on primary
tumor growth. Two million cells were injected subcutaneously on the flank of each
mouse. After 4 weeks, when primary tumors reached 0.8-1.0 cm3, tumors were
excised and mice were kept for another 3 months for lung metastses formation.
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After primary tumors were removed, the mice were kept for another 3 months
for lung metastasis. Three months later, all the mice were sacrificed and lungs were
examined for nodule formation. Metastasis rate was calculated by number of mice
with lung metastasis/total number of mice in this group. In parent cell group, 50%
metastasis rate has been observed, suggesting the malignancy and invasiveness of
this melanoma cell line. Wild-type H1 transfection significantly suppresses
metastasis with metastasis rate down to 15%. K12Q and H118F mutant H1 lost
metastasis suppression function with similar metastasis rate as parent 1205LU cells,
suggesting that exonuclease and NDPK are both involved in metastasis suppression
in vivo. Unexpectedly, P96S mutant, previously reported as contributor of increased
cell motility, still as strongly inhibit lung metastasis as wild-type H1, suggesting this
mutant may not be associated with metastasis suppression on this melanoma cell
line in in vivo model (Table 2).
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Table 2. Metastasis rate of 1205LU parent cell and transfected cell in
spontaneous metastasis model. After primary tumors were excised, mice were
kept for another 3 months to permit formation of lung macrometastasis. When mice
were sacrificed, lungs were examined for metastasis nodules. Metastasis rate was
calculated as number of mouse with lung metastasis/ total mouse number in this
group.
Cell lines

# of mouse with

Metastasis rate

lung metastasis
1205LU

6/12

50%

1205LU-WT

2/13

15%

1205LU-K12Q

5/8

62.5%

1205LU-H118F

5/10

50%

1205LU-P96S

2/9

22%
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To determine the primary tumors and metastasized nodules are consistently
expressing GFP, indicating exogenous proteins expressed in these tumor cells, the
excised primary tumors and lungs with macrometastasis were scanned for GFP
fluorescence. Compared with 1205LU parent cell with no fluorescence, all the
transfected

cell-induced

primary

tumors

and

metastasized

lung

nodules

demonstrated high intensity of fluorescence, suggesting the stability of transfected
cells in vivo. Compared with other transfected cell-induced primary tumors and lung
nodules, P96S mutant H1 transfected cell-caused tumors were observed with
relatively low fluorescence, even though the high intensity of GFP signal of the cells
in cell culture system (Figure 25).
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Figure 25. GFP is consistently expressed in both primary tumors and
metastasized

lung

nodules.

Removed

primary

tumors

and

lungs

with

macrometastasis were scanned for fluorescence with Kodak Image Station 4000.
Tumors in parent cell group which do not harbor a GFP transgene were used as
negative controls.
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4.3.10. Experimental metastasis assay demonstrated similar results as in
spontaneous metastasis assay
To confirm the results observed in spontaneous metastasis assay described
above, experimental metastasis assay was performed on nude mice with the same
1205LU parent cells and transfected cells. 2x106 cells were injected through tail vein,
and one month later, mice were sacrificed and lungs were examined for
macrometastasis. Similar results have been observed as the results of spontaneous
metastasis. Wild-type NM23-H1 suppresses lung nodule formation while K12Q and
H118F mutant H1 lost suppression function of tumor metastasis, the similar results
that have been observed in spontaneous metastasis assay. Inconsistent with the
results of spontaneous metastasis, P96S mutant H1 also lost metastasis suppression
function. Unfortunately, since the standard error in each group is very high, all the
results in this experiment have no statistic significance (Figure 26).
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Figure 26. Experimental metastasis assay demonstrated similar results as in
spontaneous metastasis assay. (A) Lung nodule numbers in each group. (B)
Representative picture of metastases on the lung from parent cell group (a and b)
and wild-type H1 group (c and d). (C) Histological images of normal lung and
metastasized nodules stained by hematoxylin and eosin.
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4.4. Discussion
Our lab has obtained some data supporting the hypothesis of DNA repair role of
NM23 in yeast. These observations need to be validated in cells derived from higher
vertebrates, preferably in human cell lines. A panel of melanoma cells, including
different stages of RGP, VGP, and MET, was screened by western blot to identify
human cell lines devoid of NM23 expression in which DNA repair activity can be
assessed, and complementation experiments conducted with a minimum of
background NM23 expression.
A significant loss of expression for both NM23-H1 and NM23-H2 has been
demonstrated in five out of seven total MET cell lines (Figure 16), suggesting that the
expression of NM23 is highly related to metastasis. This relationship was further
testified by motility assay of melanoma cell lines (Figure 17). Interestingly, WM793 cell
from VGP group which has been testified non-metastatic in experimental rodent
models has also been observed to be devoid of detectable expression of either H1 or
H2. WM793 was established from the vertical growth phase of a primary lesion of
patient 793. Cell line 1205LU, the metastatic variant of WM793, was established after
repeated passages of WM793 cells both in vitro and in vivo in nude mice
(Samasundaram et al., 2005). Because of their very low expression of NM23s, and
also the fact that they stands for premetastatic and metastatic cell lines, respectively,
these two cell lines were chosen as our study model for stable transfection.
The major goal of the project is to elucidate the molecular mechanisms
underlying metastasis suppressor activity of NM23 proteins. To determine which
enzymatic function is relevant to metastasis suppression, a panel of NM23-H1 has
been developed in our laboratory in which the primary biochemical activities of the
molecule (EXO, NDPK, and hisK) have been individually inactivated. Lysine-12 has
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been reported as the most critical amino acid of NM23-H2 that cleaves the
phosphodiester bond by transiently forming a covalent bond with DNA (Postel et al.,
2000). In NM23-H1, K12Q mutant is also demonstrated deficient of exonuclease
function. So far K12Q mutant is the only mutant we have which is exonucleasedeficient. So the transfected cells should lose metastasis suppression if exonuclease
function and DNA repair activity are involved in metastasis suppression. Unfortunately,
lysine-12 is equally critical for the NDP kinase reaction, suggesting a connection
between the two seemingly disparate enzymatic activities, NDP kinase and nuclease.
NM23 seems to use a single active site both for the cleavage of the DNA
phosphodiester backbone and for the phosphorylation of nucleotides. So, K12Q mutant
is also NDPK- and hisK-deficient. This would make the interpretation very difficult and
complicated. To address this issue, another two mutants, H118F (NDPK- and hisKdeficient) and P96S (hisK-deficient) have been used for stable transfection and later in
vitro and in vivo experiments. Comparison of the results derived from the three
mutants will provide indirect evidence for studying the mechanisms of NM23 in
metastasis suppression. E5A is a promising mutant because it was reported
exonuclease-deficient only with intact NDPK (Yoon et al., 2005). Results from this
mutant would give us direct evidence to support the relationship between exonuclease
and metastasis suppression. Now E5A mutant has been constructed, and all three
enzymatic functions have been measured. EXO is deficient in this mutant, while NDPK
and hisK are intact. Table 3 is the summary of biochemical activities of wild-type and
mutant NM23s.
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Table 3. Enzymatic function of wild-type and mutant NM23-H1s.

EXO

NDPK

hisK

WT

+++

+++

+++

K12Q

+

+

-

H118F

+++

-

-

P96S

+++

+++

-

E5A

+

+++

+++
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Transfected cells were selected under G418 for about 4 weeks to get rid of nonstably transfected cells. Acquired colonies contain cells with GFP expression
differently: 1) all the cells in one colony are GFP positive, suggesting that all cells are
stably transfected; 2) cells in one colony are partially green, suggesting that some cells
are devoid of plasmid DNA insert after multiple cell divisions; 3) all the cells in one
colony are GFP negative, suggesting that those cells are either antibiotic resistant or
pSV2Neo-transfected only. Existence of high percentage of GFP negative cells
requires further selection. To obtain cells consistently expressing wild-type or mutant
NM23, fluorescence-activated cell sorting (FACS) was performed on all the transfected
cell lines. The sorting procedure has yielded more than 95% GFP positive cells in each
transfected cell lines. Furthermore, the sorting procedure has yielded GFP positive
cells with similar intensity of fluorescence, indicating that equal amount of NM23-H1 is
expressed across cell lines (Figure 18A and B). Immunoblot analysis further validated
the forced expression of wild-type and mutant NM23-H1, which was achieved at much
higher levels than the endogenous NM23-H1 expression in the parent 1205LU and
WM793 cells (Figure 18C).
After G418 selection and cell sorting, the stably transfected cell lines were ready
for in vitro and in vivo study. But after several passages, 1205LU mutant transfected
cell lines have exhibited decreased expression of GFP, suggesting decreased NM23H1 mutant as well. This was confirmed by immunoblot result. Western blot of WCE
from 1205LU and transfected cells at passage 8 demonstrated decreased expression
of NM23 mutants as low as endogenous NM23 in parent cells while wild-type
transfected cells are expressing 30-50% more NM23 proteins than parent cells (Figure
18D). Compared with the immunoblot result from passage 3, this result suggested that
NM23 expressions are decreased in all the transfected cell lines after a while. This
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could be caused by cell line which tightly limits NM23 expression in the cell. NM23
expression must be precisely controlled in 1205LU cells. In the early passage, forced
expression broke the balance of this control system. So cells overexpress wild-type or
mutant NM23s. After a serial passage, cells have gradually gained back the balance
again and express much less amount of NM23s. This has been demonstrated by 2-D
gel which allows the separation of wild-type NM23-H1 and variant mutant NM23-H1
because of their different pI. Compared with parent 1205LU cells expressing a certain
amount of endogenous NM23-H1, all mutant transfected cell lines express equal
amount of proteins, including 50% of endogenous NM23-H1, and 50% of mutant
NM23-H1(Figure 19B). All these data suggested that 1205LU cells downregulated
endogenous NM23 expression when overexpressing mutant NM23s, without change
the total amount of NM23 expression in the cell.
After the mutant NM23 proteins were confirmed to be persistently expressed in
the transfected cells, these cells were used to perform in vivo and in vitro studies as
designed. Even though there is strong evidence to support the role of hisK function
in anti-metastatic activity, other enzymatic functions of NM23-H1 should also be
considered. It is reasonable that multiple functions of this protein are involved in the
metastasis suppression which could be a multi-step process. Our hypothesis
proposed that 3’-5’ exonuclease function of NM23-H1 play a major role in DNA repair
and maintenance of genomic stability and loss of this protein could lead to
accumulation of mutations, and thus tumor progression. Since NDPK function of
NM23-H1 is also important in keeping NTP pool in balance while imbalanced NTP
pool is the reason to induce mutations, loss of NDPK may be involved in tumor
progression. So, all these three primary enzymatic activities of NM23-H1 were
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determined systematically the relevance to antimetastatic action through both in vitro
and in vivo studies.
To study the relevance of an enzymatic function to metastasis suppression, two
human melanoma cell lines were chosen for proposed studies. 1205LU and WM793,
represent highly metastatic and premetastatic cell line, respectively. Wild-type and
variant mutant forms of NM23-H1 were stably transfected into two cell lines. Then,
parent and transfected cells were used to measure the metastatic characteristics
both in cell culture (such as motility, invasion) and in vivo, using standard
approaches of experimental and spontaneous metastasis.
Before the test of metastatic characteristic of two cell lines, transformed growth
in cell culture was determined. In vitro cell transformation is associated with certain
phenotypic changes such as loss of contact inhibition and anchorage independence,
allowing cells to form colonies in soft agar. The definition of metastasis suppressor
gene describes the way how those genes work. Re-expression of those genes back
into tumor cells should have no effect on primary tumor size, but should reduce
metastasis formation significantly. A constitutive murine nm23-1 expression
construct was transfected into highly metastatic K-1735 TK murine melanoma cells,
and these nm23-1-transfected TK clones exhibited no significant differences in
intrinsic tumor cell growth, i.e., primary tumor size in vivo, anchorage-dependent
growth rate in vitro, and anchorage-independent colony formation in soft agar in vitro
while they exhibited significant reductions in tumor metastatic potential independent
of tumor cell growth (Leone et al., 1991).
Consistent with the data previously described, transfection of wild-type and
mutant NM23-H1 has no impact on proliferation rate of two human melanoma cell

111

lines. This is very important to know because different cell proliferation rates would
confound the result of metastasis assay, such as migration assay, invasion assay, in
particular, spontaneous metastasis assay because of the long time period of this
study. For colony formation in soft agar, all transfected WM793 cell lines formed
colonies as many as parent cells. But for 1205LU cell line, wild-type, K12Q, and H118F
H1 transfected cells exhibited similar colony formation ability as parent cells; only
P96S H1 transfection demonstrated dominant-negative function and significantly
reduced colony formation. The reason is unclear because P96S mutant is hisK
deficient, while K12Q and H118F mutant are both hisK deficient. It is also unclear
whether the deficiency of colony formation ability in soft agar is the reason to cause
less lung metastases formed in nude mice in spontaneous metastasis assay
compared with another two mutants (Table 2). Another result we found is the colony
size in soft agar of two melanoma cell lines. 1205LU cell lines formed much bigger
colonies which are consisting of 100-200 cells in each single colony, suggesting the
high malignancy of this tumor cell line, while WM793 cell lines formed much smaller
colonies which are consisting of 20-50 cells in each single colony, suggesting the
much lower malignancy of this cell line (Figure 20). Because of this low
tumorigenicity of WM793 cells, we didn’t get primary tumors or lung nodules formed
in all the animal experiments, including both spontaneous metastasis assay and
experimental metastasis assay by injecting WM793 parent and transfected cells into
both nude mice and SCID mice.
Tumor cells must be able to detach from the primary tumor and invade the
surrounding tissue at the beginning of metastasis. To accomplish these steps, they
utilize a serial of proteinase, such as matrix metalloproteinases (MMPs), serine
proteinases, and cathepsins, to degrade and remold the surrounding stroma or ECM.
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In this project, both motility assay and invasion assay were employed to measure
whether transfection of variant H1 forms will have any effect on these two
characteristics of tumor cells. At room temperature, BD Matrigel™ Matrix
polymerizes to produce biologically active matrix material resembling the mammalian
cellular basement membrane. Cells behave as they do in vivo when they are
cultured on BD Matrigel™ Matrix. It provides a physiologically relevant environment
for studies of migration and invasion. For metastatic 1205LU cells, transfection of
wild-type NM23-H1 inhibits both motility and invasion significantly, consistent with its
classical metastasis suppressor actions. All the enzymatic deficient mutant H1s
inhibit motility and invasion ability of 1205LU cells as much as wild-type H1, even
though P96S mutation (hisK- deficient) was previously described to be able to disrupt
NM23-H1 mediated inhibition of motility and invasion (Freije et al., 1997). These
results suggested that any of these enzymatic functions may not have direct effect
on cell motility and invasion activities. Surprisingly, for premeatstatic WM793 cells,
transfection of wild-type or mutant H1 did not suppress cell motility. This is a result
inconsistent with metastasis suppressor activity of H1 and the reason is unknown.
Different from motility assay, transfection of wild-type H1, H 118F and P96S mutant H1
markedly inhibit invasion activity of WM793 cells, but K12Q mutant H1 disrupts this
inhibition function by wild-type and other mutant H1. K12Q is the only mutant we have
that lost exonuclease function, suggesting this enzymatic function may play some
roles in cell invasion activity directly or indirectly.
NM23 proteins may resist genetic and epigenetic changes by regulating
chromatin structure to preserve genomic integrity. We propose that 3’-5’
exonuclease may mediate the transactions with genome to oppose progression of
premetastatic cells to metastatic cells. This progression-inhibiting activity of NM23-
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H1 could be the primary role in metastasis suppression activity. WM793 cell, a VGP
cell line, makes an appropriate model system for our proposed studies because it’s
highly invasive but non-metastatic as well as the NM23s level in this cell line is under
detection. Replacing back wild-type and enzymatically-defective forms of NM23-H1
into the cell made quite stable cell lines and helped us to find out the contributions of
enzymatic functions of NM23-H1 to the process of progression. WM793 cells
reproducibly give rise to metastatic forms when placed under selective pressure,
such as cultured in protein-free (growth factor-free) medium, or repeated passaging
in vivo (Rodeck et al., 1987: Herlyn et al., 1990). Complementation of wild-type
NM23-H1 significantly blocks the progression process of WM793 cells which did
progress markedly after 4 cycle’s passage in protein-free medium. Constructs of the
3’-5’ EXO-deficient mutant, K12Q lost the function of progression blockage exhibited
by wild-type H1, possibly by disrupting DNA repair or chromatin remodeling activities
of small endogenous NM23 pools via a dominant-negative mechanism. To our
surprise, H118F mutant H1 also opposes progression of WM793 to the more
malignant phenotype after multiple cycles of selection. H118F mutant is both NDPKand hisK-deficient. If histidine kinase is not correlated to anti-progression action, then
NDPK must be involved in progression-inhibiting action. It is reasonable considering
the importance of maintenance of balanced NTP pool by NDPK to preserve genomic
integrity.
In vitro assay can only determine one or two features of cells associated with
metastasis. In vivo metastasis assay is more important because it mimics the whole
process of cancer metastasis, which is more clinically associated. In particular,
spontaneous lung metastasis recapitulates most of the steps of cancer metastasis.
So, this assay would provide more accurate and more clinically related information
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over the course of the proposed experiments. Transfection of wild-type or mutant
NM23-H1 has no effect on primary tumor growth even though K12Q mutant H1
transfected 1205LU cells reached target tumor size 5 days later. Despite the high
invasiveness and highly metastatic features of 1205LU cells, it took another 3
months for the formation of lung metastases, implying the low efficiency of
metastasis process. Interestingly, the in vivo metastasis results of 1205LU cell lines
are in very similar pattern as in vitro progression assay of WM793 cells. As shown in
table 3, wild-type H1 and P96S mutant H1 inhibit lung metastasis, while K12Q and
H118F failed to oppose metastasis of 1205LU cells, suggesting exonuclease and
NDPK, instead of hisK are the primary enzymatic functions contributing to metastasis
suppressor activity. In this animal model, all cell lines must survive and grow in a
comparatively growth factor-deprived environment, so the selective pressure placed
on these cells would cause the similar effects as in progression assay of WM793
cells. Injection of 2 millions of parent or transfected 1205LU cells through tail vein set
up a high barrier to overcome by treatments. In this experiment, even wild-type H1
transfected cells formed Lung nodules in 4 out of 10 mice, with whole lung
metastases formed in one mouse. This “overdose” injection makes less difference
between different treatments. Fewer amounts of tumor cells should be injected when
this experiment is repeated.

Copyright ©Qingbei Zhang 2006
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CHAPTER FIVE
GENERAL DISCUSSION

5.1. Summary of findings
Both tumorigenesis and metastasis are induced by genetic instability which is a
result of multiple mutational “hits”, including misregulation of gene transcription as
well as the loss of DNA repair enzymes (reviewed in Hartsough and Steeg, 1998).
Some of the well-studied oncogenes, such as ras and myc, induce both cell
transformation and metastatic competence (reviewed in Bernards and Weinberg,
2002). When tumor cells obtain further genetic alterations, some cells acquire
sufficient capacity to dissociate from the primary tumor, survive in the bloodstream,
spread through the circulation, and proliferate at the secondary site. Eventually these
tumor cells progress from benign tumor to malignant tumor with accumulating
mutations.
The hypothesis that loss of gene functions could also induce tumor progression
prompted the idea of metastasis suppressor gene. As the first metastasis
suppressor, NM23 was identified in 1988 (Steeg et al., 1988). Since then more than
fifteen suppressor genes have been identified by using many techniques, such as
differential display, microarray, microcell-mediated chromosome transfer, subtractive
hybridization, etc (reviewed in Shevde and Welch, 2003). These genes affect many
aspects of signal transduction, including pathways that are involved in invasion
(TIMPs), growth factor receptor signaling (KAI-1), the RAS-MAPK pathway (NM23)
(reviewed in Steeg, 2003), some metastasis suppressors affects cell-cell adhesion
(Cadherins) (reviewed in Jiang, 1996; Berx et al., 1996), and transcription (Brms1)
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(Meehan et al., 2004: Cicek et al., 2005), or metastatic colonization (MKK4) (Hickson
et al., 2006).
To identify differentially expressed genes that might be essential for metastasis,
murine melanoma cells were used to perform differential colony hybridization. NM23H1 was discovered on the basis of its much higher level in cells with low metastatic
activity than in their highly metastatic counterparts (Steeg et al., 1988). Low NM23H1 protein and mRNA expression correlated with a variety of tumor types, including
breast, melanoma, and gastric, ovarian carcinomas (reviewed in De la Rosa et al.,
1995). But in general, cancers containing overexpressed, mutated NM23-H1 protein
are rare events (Leone et al., 1993; Chang et al., 1994), whereas loss of expression
of NM23-H1 is a common feature of aggressive, poorly differentiated tumors
(reviewed in Hartsough and Steeg, 1998).
Over 18 years of intensive study, multiple and diverse enzymatic activities (e.g.
NDPK, hisK, and 3’-5’EXO) and regulatory activities have been ascribed to NM23s,
but the molecular mechanism underlying the metastasis suppressor activity of
NM23-H1 remains unclear. HisK is the only enzymatic activity that correlates tightly
with the motility-suppression effect of NM23-H1 even though the downstream
substrates have not been identified yet. NDPK appears to be not related
to`metastasis suppression. Our lab has demonstrated that NM23 proteins can
modestly repress gene transcription, possibly in the manner of a classical
transcription factor (Ma et al., 2002). Later, we also demonstrated NM23-H1
possesses 3’-5’ exonuclease function (Ma et al., 2004). This function is appealing as
the metastasis suppressor activity because it might have the effect on multiple
aspects of the metastatic phenotype. The most direct function would be an
antimutator activity through which genetic alterations are opposed, and thus,
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malignant progression is blocked. From our previous studies, some important
questions arise: Does NM23-H1 downregulate oncogene, such as PDGF, directly or
assist other negatively regulatory proteins to downregulate PDGF? Is the 3’-5’ EXO
function of NM23-H1 involved in DNA repair and, if so, what kind of DNA repair
mechanism is this protein involved? Is NM23-H1 associated with suppression of
tumor progression, and which enzymatic function is involved? Is the 3’-5’ EXO a key
mediator of the metastasis suppressor activity of NM23-H1? Are NDPK and hisK
functions also related to this activity?
To address all these questions systematically, first, transcriptional regulation of
NM23-H1 and another single-DNA-stranded binding protein Purα on PDGF-A chain
was determined to study the direct and indirect regulations of NM23 on oncogene
PDGF. Then, two tumor cell lines (HepG2 and HeLa) were employed to examine the
nuclear translocation and nuclear foci formation of NM23s on DNA damage. Finally,
two melanoma cell lines (prematastatic WM793 and metastatic 1205LU) were
constructed to study the impact of wild-type and enzymatically-defective forms of
NM23-H1 on metastatic phenotype and the process of metastatic progression.
Resolving these questions would add greater knowledge on relationship of cancer
metastasis and NM23, and aid in the development of mechanism-based therapeutic
strategies for cancer metastasis treatment and prevention.

5.1.1. NM23-H1 minimally downregulates PDGF-A chain promoter and has no effect
on transcriptional regulation of Purα on PDGF-A chain promoter
NM23-H2 activates transcription of c-MYC promoter by binding to its nucleasehypersensitive element (NHE) (Postel et al., 1993; Berberich and Postel, 1995; Lee
et al., 1997). NM23-H1 was first identified as a DNA-binding protein with
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transcriptional repressor activity on the PDGF-A chain promoter in our lab (Ma et al.,
2002). Basal transcription of the PDGF-A chain gene is mediated by the interplay of
positive and negative regulatory elements in the promoter region, which are GC-rich
and possess non-B DNA structure. Screening of a HeLa cDNA expression library
with the C-rich strand of a PDGF-A silencer sequence (5'-S1 nucleasehypersensitive site (SHS)) yielded three cDNA clones encoding NM23-H1, the
known protein implicated as a suppressor of metastasis in melanoma and breast
carcinoma. Transient transfection analyses in HepG2 cells revealed that NM23-H1
modestly repressed transcriptional activity driven by the PDGF-A basal promoter (82 to +8) as well as the negative regulatory region (-1853 to -883), indicating a
potential role for NM23 proteins in repressing transcription of a growth factor
oncogene, and providing a possible molecular mechanism to explain their
metastasis-suppressing effects.
Recently, cDNA microarrays were used to investigate the downstream genes
involved in NM23-mediated suppression of metastasis (Zhao et al., 2004).
Microarray analyses revealed significant as well as consistent alterations in the
expression (up- and downregulation) of more than 2000 genes which are involved in
different cellular functions: invasion and metastasis, apoptosis and senescence,
signal transduction molecules and transcription factors, cell cycle and repair,
adhesion, and angiogenesis. The results suggest the role of NM23 may play in
transcriptional regulation of a large amount of downstream genes. Furthermore,
analyses by chromatin immunoprecipitation (ChIP) in viable M14 cells (human
melanoma cell) showed DNA sequences bound to NM23 are correlated to
oncosuppressor gene p53, WT1, ING1, and NM23-H1 (Cervoni et al., 2006),
suggesting NM23 binding is involved in the transcription regulation of these genes.
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To further investigate whether NM23 facilitates other transcription factors to
bind to silencer region of PDGF-A chain promoter, and form functional silencer
complex, Purα was purified and examined for its binding and functional regulation of
PDGF-A chain promoter alone and with NM23-H1. Purα is a single-stranded DNA
binding protein and can function either as a repressor or activator depending on
promoter and cellular context. The original model proposed in our lab hypothesized
that 5’SHS silencer activity is mediated by the binding of NM23-H1, and other singlestrand specific protein, such as Purα, may serve to stabilize a DNA conformation
required for repressive interactions of the silencer with transcriptional of A-chain
gene.
Despite the sequence-specific binding of Purα with NHE fragment as well as
5’SHS silencer region in vitro (Figure 5B), transient transfection analyses
demonstrated that Purα does not appear to interact functionally with the 5’-SHS
silencer (Data not shown). Induction of NHE activity by Purα dominated over the
modest repressive activity of NM23-H1 (Figure 6A). GST-pull down assay indicated
no physical interaction between NM23-H1 and Purα (data not shown), which is not
supportive for our original hypothesis of functional silencer complex. All these
results, taken together, suggested that NM23-H1 has very weak transcriptional
regulation on growth factor oncogene PDGF, and has no effect on another positive
transcription factor Purα of PDGF-A chain promoter. Considering the broad
transcriptional regulation fuction of NM23-H1, may be its transcriptional regulation on
other genes, such as some oncogenes, or tumor/metastasis suppressor genes,
should be investigated.
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Because the effect of transcriptional regulation of NM23-H1 is very subtle, it
seems not to be an ideal model to address the profound metastasis suppressor
activity. A new hypothesis should be proposed to explain its anti-metastasis function.

5.1.2. NM23s may play a role in DNA repair
Some hereditary cancer syndromes are associated with DNA repair deficiencies
and increased chromosomal fragility (reviewed in Fearon, 1997). Xeroderma
pigmentosum (van steeg et al., 2000), Fanconi’s anemia (reviewed in Strathdee and
Buchwald, 1992), and ataxia telangiectasia (Swift et al., 1991) are inherited human
disease associated with a predisposition to cancer, chromosomal instability, and
DNA repair defects. Specifically, DNA repair gene inactivation seems lead to a
“mutator phenotype”, with a resultant increased rate of mutations in other cellular
genes, so initiation and progression of a cancerous cell may be greatly accelerated
by the inactivation of DNA repair genes (reviewed in Fearon, 1999).
During tumor progression, cancer cells must exhibit a mutator phenotype.
Everyday, approximately 105 lesions are introduced in genomic DNA in one single
cell (reviewed in Ames et al., 1995). Most of these lesions are recognized and
corrected by cellular repair mechanism. Only a very small fraction of lesions escape
and result in mutations at the time of DNA replication. These early-formed mutations
could be random and may be involved in genes maintaining genetic stability, such as
DNA repair enzymes. If so, a cascade of mutations would be ensued, and then
multiple mutations throughout the genome will be accumulated. When tumor cells
accumulate enough mutations which allow them to invade surrounding tissues,
evade from immune recognition and destruction, and to proliferate at the secondary
site, they become metastatic (reviewed in Bielas and Loeb, 2005).
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3’-5’ exonuclease activity of NM23-H1 was identified by our lab (Ma et al.,
2004). This enzymatic activity of other known 3’-5’ exonucleases can proofread for
DNA polymerase and excise the incorrectly incorporated nucleotides during DNA
replication. So, enzymes that contain 3’-5’ exonuclease activities are involved
directly in maintaining genome stability (reviewed in Shevelev and Hübscher, 2002).
Loss of this function could lead to strong mutator phenotype. In E.coli, when ndk, the
gene for NDP kinase, was disrupted, no effects on cell growth or morphology were
found surprisingly. However, a mutator phenotype was found in ndk-disruption
strains with significantly increased frequencies of spontaneous mutations to
rifampicin and nalidixic acid resistance (Lu et al., 1995). In Drosophila, mutation in
abnormal wing discs (awd) gene, 78% identical to the nm23 gene of mammals,
causes morphologically abnormal wing discs and poorly differentiated leg and eyeantenna discs, as well as defects in brain cells and ovary cells (Dearolf et al., 1988).
In mice, nm23-M1 gene knockout is not teratogenic and the pups can grow to adult
age without apparent health problems. However, they undergo a growth retardation
and knocked out females cannot feed their pups (Arnaud-Dabernat et al., 2003).
Human breast and ovarian carcinoma cells transfected with nm23-H1 exhibit
increased sensitivity to cisplatin, which is typically a phenotype of DNA repair defects
(Ferguson et al., 1996; Aebi et al., 1996). Taken together, all these phenotypic
properties listed above and the nature of NM23-H1 as a 3’-5’ exonuclease indicate
that NM23 is an obvious DNA repair protein candidate, even though the involvement
of NM23 in DNA repair has not been shown directly.
Upon damage of DNA in eukaryotic cells, several repair and checkpoint
proteins undergo a dramatic intranuclear relocalization, translocating to nuclear foci
thought to represent sites of DNA damage and repair (Barr et al., 2003). To further
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investigate the involvement of NM23 in DNA repair, nuclear translocation and
nuclear foci formation of NM23 on DNA damage were examined by using two tumor
cell lines, HepG2 and HeLa cells. Etoposide and cisplatin were used as DNAdamaging agents to treat cells for different time courses. Western blot,
immunofluorescence microscopy, and confocal microscopy results unanimously
demonstrated that nuclear relocalization of NM23 in two cell lines in response to
DNA damage. Nuclear foci bodies were also obvious in Hela cells after 4 h and 24 h
etoposide treatment even though no colocalization of NM23 and Ape1, an
endonuclease described previously interacting with NM23 in a complex (Fan et al.,
2003), was seen. All these evidence strongly suggests that NM23s play a very
important role in DNA repair.
After the role of NM23 in DNA repair was approved, a new question comes out:
what DNA repair pathway is NM23 participated in? First, base excision repair (BER)
is a possible pathway based on the nuclease feature of NM23. Site-directed
mutagenesis identified that Lys12 is the critical amino acid responsible for the
cleavage activity by NM23-H2. Substitution of lysine with glutamine completely
abrogates DNA cleavage activity (Postel et al., 2000). Similar result was found in
NM23-H1 in our lab. Enzymes that use a lysine-amine to cleave DNA belong to a
subtype of BER enzymes known as bifunctional glycosylase/lyase (reviewed in
Postel, 2003; Nash et al., 1997). It is highly likely that NM23-H1 and –H2 cleave
DNA via the glycosylase/AP lyase like mechanism. Secondly, mismatch repair
(MMR) should also be considered. MMR proteins are known to mediate the cellular
response to cisplatin damage (reviewed in Postel, 2003). Cells deficient in DNA
MMR show moderate cisplatin resistance (Fink et al., 1996; Drummond et al., 1996).
NM23 was observed to increase and translocate into nucleus in response to cisplatin
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treatment in tumor cell lines in our study, suggesting MMR is a candidate repair
mechanism for NM23; however, our previous data demonstrated that purified
recombinant NM23-H1 only digests overhanging mismatched 3' termini from doublestranded DNA templates, and does not cleave internal mismatches (Ma et al., 2004),
suggesting the limitations of the role of NM23-H1 in MMR. Finally, since NM23 was
shown to respond to etoposide damage and etoposide is a topoisomerase II usually
inducing double-strand breaks (DSB), DSB repair (DSBR) could also be one repair
pathway NM23 using as a cellular defending mechanism for DNA damage. In
mammalian cells, DSBR is mediated either by the error-free homologous
recombination (HR) or the more predominant error-prone nonhomologous end
joining (NHEJ) pathways (reviewed in Jackson, 2002). We are currently investigating
which DNA repair mechanism is NM23 involved in repairing DNA damage. It’s
possible that three pathways could be induced individually or all together depending
on different insulting. More DNA damage methods, such as ultraviolet light, ionizing
radiation, hydroxyurea, and MMS, etc, should be used to trigger cell DNA damage to
study the accurate repair pathways.

5.1.3. NM23-H1 opposes the progression of premetastatic melanoma cells, and
NDPK and/or 3’-5’ exonuclease could be the major enzyme associated with this
activity
Tumors have long been known to become more aggressive in clinical behavior
and more ‘malignant’ in their characteristics over time. This has been termed ‘tumor
progression’ and includes, among other properties invasion and metastasis, as well
as more efficient escape from apoptosis and host immune surveillance (reviewed in
Nowell, 2002). Tumor progression is driven by enhanced mutagenesis and clonal
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evolution, in which single cells expand by stepwise selections to populate a tumor
(reviewed in Bielas and Loeb, 2005). Clonal evolution of more and more aggressive
subpopulations involves multiple sequential genetic changes in a variety of genes.
Perhaps the best documented example of clonal evolution in a human malignancy is
colon cancer, in which Vogelstein and coworkers (Kinzler and Vogelstein, 1996), as
well as other laboratories, have shown a series of genetic changes associated with
the clinical progression from benign colonic polyps to invasive and metastatic
adenocarcinoma.
The clinical and histologic progression observed in the growth phases of
melanoma is hypothesized to correspond to the accumulation of genetic mutations
critical for cell proliferation, differentiation, and cell death (Clark et al., 1984). Primary
melanoma cells in vertical growth phase (VGP) are phenotypically and genetically
different from metastatic melanoma cells (MET). VGP cells must go through
progression to develop MET cells. To examine whether NM23-H1 opposes the
progression of VGP cells in vitro and whether 3’-5’ exonuclease of NM23-H1 is the
major mediator of this activity, premetastatic melanoma cell WM793 was chosen due
to the loss of expression of NM23-H1 and H2 in this cell line and stably transfected
with wild-type and variant mutant NM23-H1. Then all the transfected WM793 cell
lines alone with parent cells were exposed to protein- free medium (FBS- and
insulin-free) for selection of growth factor independence. The whole experiment took
4 rounds of selections to be finished (Figure 23). The first two selections didn’t make
significant difference between parent cell and all the transfected cell lines. The
marked difference in colony formation numbers among cell lines was obvious after
the third round of selection, and the difference in colony size was obvious after the
fourth round of selection. Significant progression of WM793 cells cultured in protein
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free medium has been demonstrated by about 10 folds increase in colony numbers
(20 colonies out of 1000 cells after first round of selection vs 200 colonies out of
1000 cells after fourth round of selection). Wild-type NM23-H1 significantly opposes
this progression process as well as P96S mutant (HisK-deficient), suggesting NM23H1 may block the accumulation of mutations as a DNA repair protein, and histidine
kinase is not involved in DNA repair function of H1 and thus prevention of tumor
progression.
As expected, K12Q mutant (EXO-deficient and NDPK-deficient) almost totally
lost the activity to oppose tumor progression. The colony formation efficiency and
colony size of K12Q mutant transfected cells were very close to that of parent cells.
These results suggested that both NDPK and/or exonuclease may be involved in
decreasing mutation rate and opposing tumor progression. Exonuclease activity of
H1 decreases mutation rate through DNA repair mechanism while NDPK activity of
H1 may lower mutation rate by keeping balanced dNTP pool to prevent
misincorporation of nucleotide during DNA replication. The involvement of NDPK in
opposing tumor progression was confirmed by the partial blockade of progression of
H118F transfected WM793 cells. Histidine kinase activity of H1 may have effects on
tumor cell motility or invasion ability, it seems to have nothing to do with decreasing
mutation rate and progression suppression.
After 4 rounds of selection in protein free medium, all the parent WM793 and
transfected WM793 cells progressed to be more aggressive and more growth factorindependent, which is one of the phenotype metastatic melanoma cells possess. But
it’s not for sure whether these cell lines have acquired enough abilities to
metastasize as 1205LU cells. It is estimated that between six and ten clonal
successions may be required to generate highly malignant human cancer cells
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(reviewed in Bernards and Weinberg, 2002). It would be interesting if those selected
cell lines could be used for in vitro and in vivo metastasis assay compared with
metastatic 1205LU cells, and also used for microarray to find out the genetic
alterations compared with the counterparts before selections.

5.1.4. NDPK and/or 3’-5’ exonuclease activities could be the mediators of metastasis
suppression
The major goal of this project is to identify the underlying molecular nature of
metastasis suppression of NM23-H1. Two melanoma cell lines were chosen for our
study model because of their very low amount of expression of NM23-H1 and H2.
After stably transfected with wild-type and variant mutant H1 and verified the protein
expression by western blot and 2D-gel, two cell lines were performed both
transformation phenotype assays and metastasis phenotype assays. Due to the very
low tumorigenicity and metastasis ability of WM793 and transfected WM793 cells
(about 5% tumor formation rate and 5% metastasis rate), we failed all the in vivo
animal experiments (including spontaneous metastasis assay and experimental
metastasis assay) with these cells by using either athymic nude mice and more
immunocompromised SCID mice.
As a metastasis suppressor gene, nm23-H1 transfection has no effect on cell
proliferation rate (Leone et al., 1991; Russell et al., 1998). However, some data
provide evidence that the nm23 genes are involved in cell proliferation (Cipollini et
al., 1997; Caligo et al., 1997), and they are preferentially expressed in the S-phase
of the cell cycle (Sorscher et al., 1993; Caligo et al., 1995). To find out whether
transfection of wild-type and mutant nm23-H1 has any effect on WM793 and 1205LU
cells, MTT assay was performed and both cell lines exhibit similar proliferation rate
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for transfected cells compared with parent cells. This is very important to know
because some of our experiments, such as selection for growth factor independence
and spontaneous metastasis assay, are very time-consuming. They took 8 months
and 4 months, respectively, to be finished. So, if the proliferation rate is different
among cell lines, then it may change or complicate the interpretation of metastasis
results.
The dislodgement of tumor cells from the primary tumor, and followed by
subsequent invasion into neighboring tissue is the first step in the formation of tumor
metastasis. Tumor cell invasion requires specific enzymes (proteases, collagenases)
to break up the barrier and to migrate through the basal lamina. In in vitro Boyden
chamber assay, only cells with ability to secret proteolysis enzymes and ability to
migrate can reach the lower chamber. As we expected, transfection of wild-type
NM23-H1 inhibited cell invasion in 1205LU and WM793 cells, consistent with the
definition of metastasis suppressor and previous data (Cantor et al., 1993).
Interestingly, in 1205LU cells, K12Q mutant H1 didn’t lose the inhibition of invasion as
we expected, but the inhibition of invasion was lost in WM793 cells, suggesting the
critical role of exonuclease activity of H1 in preventing progression of premetastatic
melanoma cells. For 1205LU cells which are metastatic cells, since the genetic
changes have occurred before H1 was overexpressed, transfection of exonuclease
deficient H1 did not cause loss of inhibition function. While in the premetastic
WM793 cells, genetic changes responsible for metastasis phenotype haven’t taken
place, so overexpression of mutant H1 had different effect on invasion inhibition.
Furthermore, P96S mutant H1 didn’t lose the invasion inhibition in both cell lines,
inconsistent with previous data from Steeg group (MacDonald et al., 1996; Freije et
al., 1997). This inconsistency could be caused by different cell types, or caused by
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having no effect of H1 transfection on proteolytic enzyme releasing in those cells
even though the motility ability may have changed.
Metastasis is a complex physiologic process and investigation of the process
has proven a challenging task. In vitro metastasis assays can only capture one or
two aspects of metastatic tumor cells instead of whole complex physiologic process.
So they are by no means comprehensive and accurate. In vivo models provide the
most physiologically relevant models for studying metastasis, especially, the
spontaneous lung metastasis, which plausibly mimics the clinical situation of
metastasis both in pathophysiology and location. Experimental metastasis (through
tail vein injection) does not recapitulate all the necessary steps that a cell needs to
perform in order to metastasize from an ectopic site. It tests the ability of the cells to
survive in the blood stream, to colonize, and to grow in the lung. In our spontaneous
lung metastasis assays, two millions of 1205LU parent cells and all the transfected
cells were injected under the skin. Five to seven days later, primary tumors formed in
every group. The growth rate of primary tumors in each group is quite similar except
K12Q mutant H1 transfected cells. Tumors in this group grew slower than other
groups after 10 day postinjection, but still reached 800 mm3 (the size ready to be
removed) on day 30 postinjection. The reason to cause this slightly slow growth is
not clear. After all the tumors reached 800 mm3, they were removed and all the mice
were kept for another 3 months to let tumor cells to metastasize to the lung. At the
end of this experiment, all the mice were sacrificed and lung metastasized nodules
were counted. As shown in table 2, wild-type H1 inhibited lung metastasis as well as
P96S mutant H1, while K12Q and H118F mutant H1 lost metastasis suppression
activity, suggesting the involvement of exonuclease and NDPK in the metastasis
suppression.
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The lung metastasis assay has the similar result as that of selection of growth
factor independence assay even though two different cell lines were used in these
two experiments respectively. There is one common point for these two experiments:
long period. Selection of growth factor independence assay took 8 months, and lung
metastasis assay took 4 months. This long period of the whole experiment means all
the tumor cells were selected under the influence of NM23-H1 or individually
enzymatic deficient mutant H1. So cells progressed with genetic changes if their
mutation rate is increased (imbalanced dNTP pool) or loss of function of DNA repair
(loss of exonuclease).
NDPK activity has long been thought as a function not relevant to metastasis
suppression. This is the first time that we provide evidence to show the relevance of
this enzymatic function to metastasis suppressor activity. The evidence includes the
involvement of H118F mutant and K12Q mutant in anti-progression of premetastatic
WM793 to metastatic phenotype in cell culture, as well as anti-metastasis in animal
model. Both of the two mutants lack NDPK activity, suggesting this enzymatic
function is essential in maintaining metastasis suppressor activity and antiprogression activity. Even though hisK is also deficient in H118F and K12Q mutants,
P96S mutant H1 (hisK-deficient only) still keeps anti-progression activity in cell culture
and anti-metastasis activity in spontaneous metastasis assay, strongly suggesting
hisK is not associated with these two activities. EXO is deficient in K12Q mutant only
and NDPK is also deficient in this mutant, so the involvement of EXO in antiprogression and anti-metastasis activities could be alone or in concert with NDPK.
The direct evidence will be provided when E5A mutant H1 is tested for antiprogression and anti-metastasis activities.
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Taken all the results together, a working model is proposed to address the
molecular mechanisms that mediate the metastasis suppressor activity of NM23-H1
(Figure 27).
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Figure 27. Molecular mechanisms that mediate metastasis suppressor activity
of NM23-H1 in melanoma cells.
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5.2. Future studies
This project is mainly focusing on the study of underlying mechanisms of
metastasis suppression of NM23-H1. Even though some questions have been
answered by our preliminary data, intensive investigations should be done to
understand the functions of NM23 in metastasis as well as the development of novel
therapeutic strategies to combat progression to the metastatic phenotype.

5.2.1. To further study exonuclease function of NM23-H1 in blocking tumor
progression and metastasis suppression
K12Q mutant is the only exonuclease-deficient mutant used in the current
project. But this mutant is also NDPK and hisK deficient. Since NDPK may be
associated with metastasis suppression and progression inhibition, it’s necessary to
use exonuclease deficient only mutant to confirm our current results. We have a
candidate mutant E5A. The mutant is previously described as exonuclease deficient
but NDPK intact. We already constructed this mutant and the biochemical functions
are under active test. Once the biochemical activities are tested and the E5A mutant
genes are stably transfected into cell lines, all the in vitro and in vivo metastasis
assays as well as progression assay will be performed to examine the role of
exonuclease in NM23-dependent metastasis suppression.
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5.2.2. To compare the gene profile and protein expression profile in NM23-H1
deficient and proficient cell lines and to functionally validate some of these NM23dependent genes
Previously, WM1158, another nm23-deficient metastatic melanoma cell line,
and WRO82 cell line were infected with the Ad5-H1 adenoviral expression vector.
Analysis of mRNA expression profiles revealed that 13 out of total 46 downregulated
genes were associated with transcription, DNA repair, and replication. Microarray
analysis will be performed for more cell lines, such as WM793, 1205LU, in pair wise,
to compare the gene profile, as well as parent cells compared with transfected cells.
Furthermore, WM793 parent and transfected cell line could be compared with the
counterpart cell lines after 4 cycles of selection. Since cell progression was seen
obviously after 4 cycles of selection, genomic alterations should be found by
comparing cells before and after selection. Besides genomic technologies,
proteomics may also be applied to identify molecular factors involved in nm23associated metastasis suppression. After the nm23-dependent genes or proteins are
found, functional validation will be performed by transfecting back those genes
(downregulated genes in metastatic cells) or knocking out those genes (upregulated
genes in metastatic cells) to see whether metastasis function will be suppressed in
the cells.

5.2.3. To investigate whether introduction of NM23-H1 facilitates apoptosis following
genotoxic stress
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Recently, NM23-H1 was proposed as an endpoint effector of apoptosis (Fan et
al., 2003). When cytotoxic T cell or natural killer cell attacks target cell by releasing
granzyme A, granzyme A cleaves NM23-H1 inhibitor, SET, and unleashes NM23-H1
(activated DNase) to induce caspase-independent apoptosis. This finding suggests
the possibility that immune surveillance may be compromised as a consequence of
NM23-deficiency. To investigate whether introduction of NM23-H1 induces apoptosis
under genotoxic stress, activation of caspase-8 will be measured across the 1205LU
cell panel as an early indicator of apoptotic activity. Apoptosis will be measured
under basal conditions and in response to genotoxic insult, such as etoposide,
cisplatin and UV light. These assays should determine the extent to which 1205LU
cells might be resistant to programmed cell death in the absence of NM23-H1 and its
attendant 3’-5’ EXO activity. In in vivo assay, examination of melanoma cell
apoptosis at early times after lung tissue seeding of melanoma cells provides insight
into tumor outgrowth at later stages. 1205LU cell panel will be injected into nude
mice through tail vein. One week later, lung tissues will be excised and the levels of
apoptotic cells will be examined by Dead-End TUNEL Assay in frozen tissue
sections (Ervin and COX, 2005).
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